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3Summary
Human immunodeficiency virus type 1 (HIV-1) has been the cause of a pandemic for
more than 30 years. Without proper treatment most HIV-1 infected individuals will un-
avoidably progress to a condition called acquired immunodeficiency syndrome (AIDS) and
eventually die. At the end of 2013, globally still more than 30 millions of people are living
with HIV and more than one million people have died of AIDS (WHO 2014).
Fortunately, although HIV-1 infection currently cannot be cured, proper and continuous
treatment with antiretroviral drugs can fully suppress viral replication and prevent disease
progression. Standard treatment is a combination of antiretroviral treatments (cART),
mostly consisting of two nucleos(t)ides analogue inhibitors (NRTIs) and one potent agent
from either the protease inhibitors (PIs), the non-nucleotide analogue inhibitors (NNR-
TIs), or other new drug classes. Modern drugs are more potent and less toxic and thus
are more appropriate for long-term usage. However, due to the virus’s ability to mutate
rapidly and to generate large genetic diversity, drug-resistant mutants can emerge.
Drug resistance is a major concern jeopardizing the treatment success. There are two types
of drug resistance: acquired and transmitted. Whereas the former is mostly selected, e.g.,
due to suboptimal treatment or insufficient adherence, the latter is transmitted from either
a treatment-failing or treatment-na¨ıve individual who carries the drug-resistant virus. In
most industrialized countries acquired drug resistance has been reduced substantially in
terms of prevalence thanks to successful treatment; however, on the contrary, prevalence
of transmitted drug resistance has not declined. This is contradictory to the general hy-
pothesis that transmission of drug resistance is primarily driven by patients with acquired
drug resistance. In Research Project 1 we analyzed the resistance and clinical data from
2421 recently-infected, treatment-na¨ıve and 5399 treatment-failing patients and throughly
studied prevalence of transmitted drug resistance over 15 years in Switzerland, including
its time trend and associated risk factors and its association with the viral burden of
treatment-failing patients. We found that prevalence of transmitted drug resistance fluc-
tuated considerably over time; it dropped sharply when a new drug class was introduced
but increased in the years when no new drug class was introduced. Therefore, introduction
of new drug classes kept transmission of drug resistance low over time and will most likely
be needed in the future to maintain low drug resistance transmission rates. Moreover, we
found that treatment-na¨ıve patients also represent a major transmission reservoir for drug
resistant viruses, mostly harboring low-fitness-cost mutations.
In Research Project 2 we determined the persistence behavior of 17 transmitted drug
resistance mutations by calculating reversion rates in treatment-na¨ıve patients, and es-
timated the association of the persistence with the predicted fitness cost of individual
mutations in the genetic backgrounds in which they occurred using a previously published
machine-learning algorithm. We could show strong variations in the persistence behav-
ior of transmitted drug resistance mutations and the significant association of persistence
with predicted fitness costs. Specifically, we found that even mutations of the same type
tended to persist longer if they occurred in a genetic background where they caused weak
fitness costs.
In Research Project 3 we moved from transmitted to acquired drug resistance. Over time,
the most recommended and used NRTI backbones for firstline ART have changed. From
the oldest combination zidovudine(AZT)/lamivudine(3TC), to the tenofovir(TDF)/3TC,
to recently abacavir(ABC)/3TC and TDF/emtricitabine(FTC). The daily dosing fre-
quency and the daily number of pills that need to be taken (pill burden) vary substantially
among these four combinations, which could be an important confounder when studying
the relative efficacy. We thus compared the relative treatment efficacy rearding viral re-
4sponse and the emergence of NRTI resistance and adjusted the model for dosing frequency
and pill burden. Our results showed robust associations of pill burden and ethnicity with
treatment efficacy.
In conjunction, we performed in depth analyses of the epidemiology of transmitted drug
resistance over time, studied the association of fitness costs with differential persistence
behavior of transmitted drug resistance mutations, and compared the risk of having viro-
logical failure and emergence of acquired drug resistance among different NRTI backbones.
5Zusammenfassung
Das Humane Immundefizienz-Viurs (HIV) ist die Ursache einer globalen Epidemie seit
rund 30 Jahren. Eine HIV-Infektion wird sich, ohne richtige Behandlung, zu AIDS en-
twickeln, und die Infizierten werden mit wenigen Ausnahmen schliesslich daran sterben.
Ende 2013 leben u¨ber 30 Millionen Menschen mit HIV-Infektion und u¨ber eine Millionen
Menschen starben an AIDS (WHO 2014).
Eine HIV-Infektion kann nicht ganz geheilt werden, allerdings kann mit angemessenen
und kontinuierlichen Therapien die Vermehrung der HI-Virus unterdru¨ckt werden, und
dadurch die Progression der Infektion unterbinden. Eine Standardtherapie besteht in
der Regel aus drei Medikamenten, am ha¨ufigsten jeweils zwei nukleosidische Reverse-
Transkriptase-Inhibitoren (NRTI) plus einen nicht-nukleosidische-Reverse-Transkriptase-
Inhibitor (NNRTI) oder einen Proteaseinhibitor (PI). Modernere Therapien sind im Ver-
gleich mit a¨lteren Medikamenten potenter und haben weniger Lanzeittoxizita¨t, und sind
somit besser geeignet fu¨r langja¨hrige Behandlungen. Dennoch ko¨nnen gelegentlich Re-
sistenzen gegen diese Medikamente entstehen.
Die Resistenzen sind problematisch, denn sie gefa¨hrden den Erfolg der HIV-Therapien. Es
gibt zwei Arten von Resistenzen: erworbene und u¨bertragene Resistenz. Die Erstere wird
durch antiretrovirale Medikamente selektioniert, wohingegen die Letztere von einer Per-
son u¨bertragen wird, die resistente Viren in sich tra¨gt. In den meisten industrialisierten
La¨ndern konnte die Pra¨valenz der erworbenen Resistenz in den letzten Jahren durch erfol-
greiche Therapien reduziert werden. Dies ist allerdings nicht der Fall fu¨r u¨bertragene Re-
sistenz. Dieses Pha¨nomen widerspricht der allgemeinen Hypothese, dass Resistenz prima¨r
von den Therapie-Versagern u¨bertragen wird. Im Forschungsprojekt 1 haben wir die Re-
sistenzdaten und klinische Daten von 2421 neu infizierten und unbehandelten Patienten
und 5399 Patienten, die eine fehlgeschlagene Therapie erlitten haben, analysiert. Wir
haben die Pra¨valenz der u¨bertragenen HIV-Resistenz u¨ber den Zeitraum von 15 Jahren
in der Schweizerischen HIV-Kohortenstudie untersucht, inklusive assoziierter Risikofak-
toren, und die Assoziation mit der Viruslast von Therapie-Versagern, studiert. Wir haben
festgestellt, dass die Pra¨valenz der u¨bertragenen Resistenz stark geschwankt hat. Sie ist
jeweils angestiegen in der Zeit, wa¨hrend der keine neue Medikamentenklasse eingefu¨hrt
wurde, und hat andererseits jeweils abgenommen, wenn neue Medikamentenklassen einge-
setzt werden konnten. Diese Resultate deuten darauf hin, dass einerseits die Einfu¨hrung
einer neuen Medikamentenklasse die U¨bertragungsrate der Resistenz zwar fu¨r eine gewisse
Zeit reduziert, anderseits bedarf es sta¨ndig neuer Medikamente, um die U¨bertragungsrate
tief zu halten. Wir haben zusa¨tzlich herausgefunden, dass unbehandelte Patienten ein
wichtiges Reservoir fu¨r u¨bertragene Resistenzen bilden, vor allem fu¨r solche, die tiefere
Fitnesskosten haben.
Im Forschungsprojekt 2 haben wir mit in vivo Daten von unbehandelten Patienten die Per-
sistenz von 17 u¨bertragenen Resistenzmutationen bestimmt, indem wir die Reversionsraten
kalkuliert haben. Ein machine-learning Algorithmus wurde benutzt, um die Fitnesskosten
individueller Mutationen in dem genetischen Hintergrund, in dem eine Mutation auftritt,
vorauszuberechnen. Wir haben gezeigt, dass die Persistenz einer Mutation stark variiert
und mit den Fitnesskosten assoziiert ist. Wir haben auch gezeigt, dass sogar der gleiche
Mutationstyp eine la¨ngere Reversionsrate hat, wenn sie in einem genetischen Hintergrund
auftritt, der tiefere Fitnesskosten verursacht.
Im Forschungsprojekt 3 haben wir uns auf erworbene Resistenz konezentri-
ert. Im Speziellen haben wir die Wirksamkeit und die Resistenzbildung der
zu unterschiedlichen Zeiten am ha¨ufigsten gebrauchten NRTI-Kombinationen, Zi-
dovudine (AZT)/Lamivudine(3TC), Tenofovir(TDF)/3TC, Abacavir(ABC)/3TC und
6TDF/Emtricitabine(FTC), in Abha¨ngigkeit von verschiedenen Faktoren verglichen. Wir
untersuchten einerseits das virologische Versagen (engl: virological failure, VF) und an-
dererseits die Bildung von NRTI-Resistenz zwischen den vier NRTI Gruppen. Diese Kom-
binationen unterscheiden sich auch durch die Dosierungsfrequenz und die Tagesanzahl der
einzunehmenden Pillen (engl: pill burden). Wir haben diese beiden Faktoren in die Anal-
yse deswegen miteinbezogen. Unsere Resultate haben gezeigt, dass der ”Pill-burden” und
die Ethnie eine wichtige Rolle spielten fu¨r das Therapieversagen und fu¨r die Entwicklung
von Resistenz.
Zusammengefasst habe wir detailliert die Epidemiologie der u¨bertragenen Resistenzen im
Verlauf der Zeit analysiert. Weiter haben wir die Assoziation der Fitnesskosten mit der
verschiedenen Persistenz der Resistenzmutationen in vivo studiert. Zuletzt haben wir das
Risiko, das zum Versagen einer Therapie und zur Bildung erworbener Resistenzmutationen
fu¨hrt, bei verschiedenen NRTI Kombinationen verglichen.
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1
HIV Infection
The infection by the human immunodeficiency virus-1 (HIV-1) ultimately leads to death
in almost all patients if untreated. Globally, to date almost 78 million people have been
infected with HIV and of those about 39 million people have died (WHO 2014). In 2013,
still more than 30 million people are living with HIV and more than 1 million have died of
AIDS (WHO 2014). It was estimated that 2.7 million people have become newly infected
in the year 2010; most of them live in low- and middle-income countries (UNAIDS 2013).
HIV causes the acquired immunodeficiency syndrome (AIDS) [1–3]. It induces a CD4
decline over the years that results in severe immunodeficiency followed by opportunistic
diseases such as bacterial, fungal and viral opportunistic infections and HIV-associated
cancers [4–7]. Combination antiretroviral treatment introduced in 1996, a combination of
three different antiretroviral agents, has fundamentally changed the course of disease and
has turned a deadly disease into a chronic disease. With proper treatment nowadays, viral
replication in most patients can be fully suppressed [8–10]. This results in a recovery of
the CD4 T cells in patients who had already suffered from AIDS defining illnesses and
prevents a CD4 cell decline in patients who are diagnosed during early disease stages.
HIV infects people through the transfer of body fluids, including blood, semen, pre-seminal
fluid, rectal fluid, vaginal fluid, and breast milk. The major transmission routes are sexual
contact (including men having sex with men and heterosexual transmission), intravenous
drug abuse, and mother to child transmission. Data from the Swiss HIV Cohort Study
showed that 61% of male patients were infected via homosexual contact, 24% male and
76% female patients via heterosexual contact, and 9-10% of patients in both genders via
intravenous drug abuse. In the early days, HIV was also transmitted by contaminated
blood products. However, HIV is not spread by air, water, saliva [11], sweat, casual body
contacts like shaking hands and hugging, or contact with the same toilet seats.
Though HIV infection has been notorious for almost 30 years, its advanced treatment is
proven to be able to considerably reduce mortality [5, 12, 13]
1.1 Origin and history
The HIV-1 epidemic is assumed to originate from a crossover of the simian immunodefi-
ciency virus (SIV) from chimpanzees to humans [14–16]. In the early 1980s, AIDS was
identified in the United States and started to cause global attention [17–19]. In 1983
Gallo’s and Montagnier’s labs isolated independently for the first time the virus causing
AIDS from AIDS patients [20, 21]. In 1986 this virus was named HIV.
11
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Figure 1.1: Global distribution of HIV-1 subtypes and circulating recombinant forms [34]
1.2 Types and subtypes
There are two types of HIV, type 1 and type 2. While HIV-1 and HIV-2 can both cause
AIDS, the former was found to be much more prevalent [22], virulent and infectious [23].
Due to the low infectivity HIV-2 remains mostly restricted to West Africa [24]. The no-
torious pandemic HIV infection is actually caused by HIV-1, and in particular, the group
M.
HIV-1 is divided into four groups based on genetic differences: M, N, O, and P [25]. Infec-
tions with HIV-1 other than from the group M are extremely rare, and are only found in
individuals from Cameroon [25]. Group M is further divided into nine subtypes as well as
many circulating recombinant forms among subtypes due to recombination [16]. There is
no conclusive evidence that one subtype is more infectious than the others. All subtypes
can be reliably treated with current antiretroviral agents [26–28].
The distribution of HIV subtypes and circulating recombinant forms is illustrated in Fig-
ure 1.1. Worldwide ≈ 50% of the HIV-1 infected population harbors subtype C viruses
making subtype C the most dominant subtype, followed by subtype A (≈ 12%) and sub-
type B (≈ 10%) [16, 29]. However, subtype C is mostly concentrated in southern Africa
and India. Subtype A and A recombinant forms are predominant in central and east-
ern Africa and in eastern Europe [16]. The largest diversity can also be found in central
Africa where all subtypes and many recombinants are present [29, 30]. On the contrary,
subtype B is the most widely spread and well studied subtype because it is the dominant
subtype in western and central Europe, the Americas, and Australia [16, 30]. However,
with increasing tourism and networks between these countries and low- and middle-income
countries, an increasing prevalence of non-B subtypes has appeared in many high-income
countries [31–33].
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1.3 The natural course of HIV-1 infection
There are several different phases from a new HIV-1 infection progressing to AIDS, each
being characterized with distinct disease attributes. Although the time course of an in-
fection can vary substantially from person to person, the general progression steps are
fundamentally similar (Figure 1.2).
The HIV-1 infection usually starts with an asymptomatic phase (referred to as the eclipse
phase) that lasts one to two weeks. The virus can replicate and migrate in the blood
freely because the immune response is not active yet. During this phase, viral RNA in the
plasma cannot be detected by any clinical diagnostic assay [35].
The following weeks are characterized by a short drop of CD4 counts and a sudden in-
crease of viremia. This phase is referred to as the primary or acute infection phase. About
60-80% of cases present unspecific symptoms resembling a ”viral syndrome”, e.g., acute
mononucleosis including fever, headaches, sore throat, skin rash, lymphadenopathy, diar-
rhea, etc [36, 37]. The immune response begins to be active at the time of the viremia
peak, leading to the production of a large number of activated CD4 cells. As a result of
both partial control of the immune system and exhaustion of activated CD4 cells, high
viremia decreases strongly at the end of this phase (≈ 100 days following the infection)
and begins to plateau [38]. During this phase, there is generally a sequential gain in pos-
itive clinical diagnostic assays, starting from viral RNA measured by PCR, to p24 viral
antigen measured by enzyme-linked immunosorbent assay (ELISA), to HIV-1 specific an-
tibody detected by ELISA, and finally to HIV-1 specific antibody detected by ELISA and
western blot [35].
The next phase following the primary infection can last up to decades and is thus called the
phase of clinical latency. This phase is usually asymptomatic. Over time, viremia starts
to increase steadily. Everyday there is a large number of activated CD4 cells becoming
infected and dying. Most infected individuals will gradually progress to the phase of AIDS
(median time: 8-10 years) with the exception of elite controllers. Elite controllers are a
rare group of individuals who are able to maintain a high number of activated CD4 cells
and a low level of viremia. Unfortunately, it is not known exactly how these people can
control the infection better than others without progressing to the final phase, AIDS [1–3,
39–41].
When CD4 cell counts drop to below ≈ 200/µ`, severe immunodeficiency occurs. AIDS
defining illnesses and occasionally other opportunistic infections will start to show [42–44].
Control of HIV through the immune system is almost completely lost causing viremia to
start to increase rapidly. Eventually, an untreated patient will inevitably die.
1.4 Disease progression and monitoring
In the initial phase of the HIV-1 infection the viral population in most cases (60-90%
in sexual transmission) is monomorphic [45, 46]. With time genetic diversity gradually
accumulates until a plateau is reached [47, 48]. Therefore, genetic diversity can be used
as an indicator to determine the age of the infection (more on genetic variability see
Chapter 4.1). The ambiguity score, which was developed in our group by Kouyos et al.,
is a simple measure for viral diversity based on ambiguous nucleotide calls from routine
population sequencing as performed for genotypic resistance testing [49]. The infection
age was found to be correlated with the ambiguity score. It is a useful tool to distinguish
between recent and chronic infection in patients lacking seroconversion data, which is
often the case in large cohort studies. This difficult to answer but highly relevant question
can now be addressed more appropriately without further costs, in particular for research
14 CHAPTER 1. HIV INFECTIONNatural Course of an HIV Infection
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Figure 1.2: The natural time course of HIV infection
(adaped from [38])
purposes [50–52].
The two major surrogate markers for disease progression are the CD4 cell count and the
viral load (HIV-plasma RNA). The latter is also the key parameter to monitor treatment
success [53] and adherence to therapy (for treatment recommendations see Chapter 3.4).
2
HIV-1 Pathogenesis
2.1 Virus structure
HIV belongs to the group of retroviruses and possesses a genome of single-stranded RNA,
which is 9749 bp long. The virus comprises two copies of single stranded RNA enclosed by
three layers of protection. From the innermost to the outermost layer, we have a conical
capsid composed of the viral protein p24, a matrix composed of the viral protein p17,
and finally an envelope composed of some of the host cell membrane and glyocoproteins
including gp120 and gp41 [54]. Together with the viral RNAs, accessory gene products
such as Vif, Nef, Vpr and essential viral proteins are enclosed within the capsid. Gp120 is
anchored to the viral membrane, or envelope, via non-covalent bonds with the transmem-
brane glycoprotein, gp41. Three gp120s and gp41s form a trimer of heterodimers [55, 56].
Approximately 6-10 of these trimers sit on a virion and form the envelope spikes that are
essential for entering new host cells [57, 58] (Figure 2.1).
HIV genome comprises three major genes, encoding functional and structural proteins,
and other regulatory genes (Figure 2.2). The gag gene encodes the capsid and matrix
materials, the pol gene is responsible for essential viral enzymes including reverse tran-
scriptase, protease and integrase, and the env gene produces envelope-associated proteins,
gp120 and gp41.
2.2 Life cycle
The life cycle of HIV-1 is composed of several steps:
1. viral entry into the host cell
2. reverse transcription of the viral genome
3. integration of the viral DNA
4. assembly, release, and maturation
For entry, HIV needs both the CD4 glycoprotein and a chemokine receptor on the sur-
face of the target cell including CD4 cells, macrophages, and dendritic cells. After gp120
successfully binds to the receptor CD4 molecule on the target cell surface [59, 60], gp41
undergoes a significant conformational change allowing the co-receptor binding, which is
mediated partially by the V3 loop attached to the gp120 [61, 62]. Following the co-receptor
binding gp41 continues to fold into six helix bundles bringing the viral membrane and the
15
16 CHAPTER 2. HIV-1 PATHOGENESIS
Figure 2.1: HIV structure
(from U.S. department of health and human services: http://web.archive.org/web/20050531012945/
http://www.niaid.nih.gov/factsheets/howhiv.htm)
Figure 2.2: HIV-1 gene map
(from http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html)
2.3. LATENT HIV RESERVOIR 17
host cell membrane closer [63, 64] and leading finally to the fusion of the two membranes.
An entry pore is created that allows the viral capsid to enter the target cell [65].
There are two kinds of chemokine receptors that HIV uses as the co-receptor for entry,
CCR5 and CXCR4 – this phenomenon is called viral tropism. Viruses that use CCR5 are
called R5 tropic, viruses that use CXCR4 are called X4 tropic, and viruses that are able
to use both CCR5 and CXCR4 are called R5X4 dualtropic [66–68]. With rare exceptions,
most viruses being transmitted use CCR5, either completely or partially [45, 46]. Viruses
using CXCR4 emerge later in the course of the infection with a percentage of around
50% [69–71].
After entry, viral enzymes along with the viral genome are released into the host cell.
Reverse transcriptase transcribes single-stranded RNA into single-stranded cDNA, and
subsequently synthesizes a sense DNA for the antisense cDNA creating a double-stranded
DNA. This DNA is then transported into the cell nucleus and integrated into the host
genome by the viral enzyme integrase [72, 73]. The integrated viral DNA is called the
provirus. The next steps are executed by taking advantage of functions of human RNA
polymerase and tRNA: First, the HIV provirus is transcribed into mRNA, which is spliced
into smaller pieces so that the smaller RNA pieces can be transported from the nucleus
to the cytoplasm. In the cytoplasm, viral proteins are translated via human tRNAs. The
viral regulatory protein Rev is one of the viral proteins that are translated the earliest be-
cause this protein carries out a very important function, namely exporting the unspliced
viral mRNA from the nucleus to the cytoplasma [74, 75]. Once the full-length mRNA
reaches the cytoplasm, large proteins like Gag and Gag-Pol proteins can then be trans-
lated. Finally, the full-length RNA together with Gag and Gag-Pol proteins and viral
protease bud through the host cell membrane [76].
Accompanying (or immediately following) budding, the final step of the life cycle be-
gins [77]. Protease cleaves large viral protein precursors into structural proteins and func-
tional enzymes. Only after the maturation process, the virus is infectious [78–80].
2.3 Latent HIV Reservoir
The HIV-1 latent reservoir is formed by replication-competent viruses accumulated pri-
marily in resting memory CD4 T cells. Due to the long lifespan of resting CD4 cells, these
viruses are more stable than the actively replicating viruses, and show only minimal decay
even under successful antiretroviral treatment [81]. Thus, even when viremia levels are
suppressed below the detection limit, the latent reservoir is sufficient for a lifelong persist-
ing infection [82, 83]. With current treatment options, eradication of the latent reservoir
cannot be achieved [83–85].
Latency is established at very early stage after infection [86, 87], when an active CD4
cell becomes infected and survives long enough to revert back to the resting state [88].
However, following infection of the resting CD4 cells, sometimes a block occurs probably
at the stage of importing the viral DNA into the nucleus. This results in the preintegra-
tion latency [89]. Whereas the preintegration latency is characterized with unintegrated
HIV-1 DNA and is of little clinical relevance due to its labile nature, the postintegration
latency establishes a stable latent reservoir with integrated viral DNA, which is reversibly
silenced, in the host genome [90, 91].
Evidence was found to support that transcription of unspliced RNA can occur constantly.
This phenomenon is partially responsible for the residual viremia (average level of 1
copy/m`) [88, 92, 93], which cannot be reduced by treatment intensification [94–96]. More-
over, during active viral replication, new variants that evolve over time also continuously
enter the latent reservoir [97]. This means that in treatment-failing patients with drug re-
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sistance, resistant viruses are deposited in the latent reservoir and can potentially reemerge
if an antiretroviral drug that viruses are resistant to is used.
In conclusion, latency is responsible for the need for lifelong treatment of HIV-1 infected
individuals (i.e., there is viral rebound after therapy discontinuation [98]) and persistence
of drug resistance (also see Chapter 3 and Chapter 4 for antiretroviral treatment and drug
resistance, respectively).
3
HIV Antiretroviral Treatment
HIV-1 infection is a lifelong infection for which there is currently no cure. Today there
are more than 25 antiretroviral agents from 5 different drug classes available to treat
HIV-1 infected patients. Although it is not possible to eliminate HIV-1 infection, potent
combination of antiretroviral treatment (cART) can fully inhibit viral replication and
stop viral evolution [98]. Moreover, effective treatment can also reconstitute the immune
system and prevent its destruction [53]. Generally, plasma HIV-1 RNA in treated patients
is below the detection limit of the most sensitive assays used in clinical practice. However,
if patients stop treatment, plasma HIV-1 viral load rebounds eventually within days to
weeks in the majority of patients [99]. Factors leading to treatment failure (i.e., when
undectable plasma HIV-1 RNA levels are not achieved or maintained) are, e.g., non-
adherence, drug intolerability, drug-drug interactions with another HIV-1 antiretroviral
agent or other medications that reduce optimal drug levels in the blood, transmitted drug
resistance, emergence of drug resistance on treatment, dosage errors, and drugs of low
potency [53].
3.1 Available drugs
The first HIV-1 antiretroviral drug, zidovudine or azidothymidine (AZT), was approved in
Switzerland in 1987 [105, 106]. AZT is a nucleoside analogue reverse transcriptase inhibitor
(NRTI), which blocks the reverse transcriptase’s enzymatic function by terminating the
DNA polymerization. Many drugs have been developed and approved over time [53].
To date, 29 approved and registered HIV antiretroviral drugs including co-formulated
tablets are prescribed for HIV-1 infected patients in Switzerland. Table 3.1 summarizes
all approved single-formulated HIV antiretroviral drugs in Switzerland.
In addition to these drugs, several co-formulations containing fixed doses of two or three
drugs from one or two drug classes have also been developed. See Table 3.2 for the
registration time line.
3.2 Mechanisms of antiretroviral agents
All HIV antiretroviral agents are categorized into classes according to their targets and
functions. NRTIs are mostly nucleoside analogues with the exception of tenofovir being
a nucleotide analogue. NRTIs need to be phosphorylated and are only active as triphos-
phates. They compete with the natural deoxynucleotides (dNTP) in hosts for incorpora-
tion into the growing viral DNA chain. However, because NRTIs lack a 3’-hydroxyl group
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Generic Name Abbreviation Brand Name Registered Year Drug Class 
Zidovudine AZT Retrovir 1987 NRTI 
Didanosine DDI Videx 1992 NRTI 
Saquinavir SQV Invirase 1996 PI 
Lamivudine 3TC 3TC 1996 NRTI 
Stavudine d4T Zerit 1996 NRTI 
Indinavir IDV Crixivan 1996 PI 
Ritonavir RTV Norvir 1996 PI 
Nelfinavir NFV Viracept 1997 PI 
Nevirapine NVP Viramune 1997 NNRTI 
Efavirenz EFV Stocrin 1998 NNRTI 
Amprenavir APV Agenerase 1999 PI 
Abacavir ABC Ziagen 1999 NRTI 
Lopinavir + Ritonavir LPV/RTV Kaletra 2000 PI 
Didanosine ddI Videx Ec 2001 NRTI 
Tenofovir TDF Viread 2002 NRTI 
Enfuvirtide T-20 Fuzeon 2003 Fusion Inhibitor 
Atazanavir ATV Reyataz 2004 PI 
Emtricitabine FTC Emtriva 2004 NRTI 
Fosamprenavir FOS-APV Telzir 2005 PI 
Tipranavir TPV Aptivus 2005 PI 
Darunavir DRV Prezista 2006 PI 
Maraviroc MVC Celsentri 2008 CCR5 antagonist 
Raltegravir RGV Isentress 2008 InSTI 
Etravirine ETR Intelence 2008 NNRTI 
Rilpivirine RPV Edurant 2013 NNRTI 
Elvlitegravir a EVG - 2013 InSTI 
Dolutegravir DTG Tivicay 2014 InSTI 
 
a. Only available in the single tablet regimen containing EVG, TNF, FTC 
Table 3.1: Approved single-formulated HIV antiretroviral drugs
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Brand Name Containing drugs Registered Year Drug Classes 
Combivir AZT, 3TC 1998 NRTI 
Trizivir AZT, 3TC, ABC 2000 NRTI 
Kivexa ABC, 3TC 2005 NRTI 
Truvada TDF, FTC 2006 NRTI 
Atripla TDF, FTC, EFV 2009 NRTI, NNRTI 
Eviplera TDF, FTC, RPV 2011 NRTI, NNRTI 
Stribild TDF, FTC, EVG 2013 NRTI, InSTI 
Triumeq ABC, 3TC, DTG 2015 NRTI, InSTI 
 
Table 3.2: Approved co-formulated HIV antiretroviral drugs
on the deoxyribose unlike the natural dNTP, the incorporation of a NRTI prevents the
next incoming dNTP from forming the 5’-3’ bond, which is essential for DNA synthesis.
As a result, after incorporation of NRTI into the DNA chain, DNA polymerization is ter-
minated [107–109].
Protease inhibitors (PI) are a class of drugs that bind the viral protease and prevent
protease from cleaving the viral protein precursors. This class of drugs binds to the
substrate/inhibitor binding site of the protease and reduces the enzyme’s catalytic activ-
ity [110, 111]. The first PI, Saquinavir, was developed and introduced after NRTI in 1996,
being the second class of HIV antiretroviral drugs. In 2000, a milestone was set when
ritonavir-boosted PIs were introduced [112] because boosted PIs had increased efficacy,
high barrier of resistance, and a reduced pill burden and dosing frequency [113–115]. Re-
cently, a novel booster, cobicistat, was developed and demonstrated similar efficacy to
RTV. Since it has no antiretroviral activity in vitro, it eliminates any potential for PI
resistance to emerge [116, 117].
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the third class of antiretro-
viral drugs that was developed. Unlike NRTIs, NNRTIs employ a different mechanism
to block reverse transcriptase’s enzymatic function. NNRTIs are small molecules with
strong affinity for a hydrophobic pocket, which is located near the reverse transcriptase’s
catalytic domain. Binding of NNRTIs to the reverse transcriptase directly influence the
flexibility of the enzyme so that the distorted part cannot bind to DNA, resulting in the
inhibition of DNA polymerization [118, 119].
In addition to the aforementioned classes that comprise the most frequently used HIV
therapies, drugs targeting other functional parts along the HIV life cycle have also been
developed. One of the novel classes is the entry inhibitors, which consist of maraviroc, a
CCR5 antagonist, and enfuvirtide, a fusion inhibitor. Maraviroc is the only antiretroviral
drug so far that targets a host cell compartment, i.e., CCR5, instead of the virus. CCR5 is
a co-receptor for most HIV strains on the surface of human macrophages and T-cells and
is necessary for the virus to enter the host cell. Maraviroc binds to CCR5 and prevents
CCR5 from associating with the viral envelope glycoprotein [120, 121]. However, maravi-
roc is not effective against HIV with X4 or R5X4 tropism. Therefore, a HIV tropism test
is mandatory before a patient starts the treatment containing maraviroc. Enfuvirtide, on
the other hand, works at the final stage of the entry process; it inhibits membrane fusion.
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Enfuvirtide is a peptide consisting of 36 amino acids that binds to the HR2 region of gp41.
The creation of an entry pore is thus prevented, keeping the capsid of the virus out of the
target cell [122]. The advantage of enfuvirtide is that its target is novel, thus making it
important especially as salvage treatment for patients with multiple resistances. However,
as enfuvirtide needs to be injected twice a day due to a short half-life and has relatively
low potency, its clinical application is very limited today [123].
Another novel class is the integrase inhibitors (Integrase Strand Transfer Inhibitor, InSTI),
which prevent viral DNA from being integrated into the host DNA. The first integrase in-
hibitor, raltegravir, was approved by Swissmedic in 2008 first for salvage therapy and has
resulted in superior viral suppression with optimized background therapy than optimized
background therapy alone for at least 48 weeks [124].
3.3 Combination of antiretroviral drugs
Before the first PI or NNRTI were developed and approved, HIV-1 infected patients were
treated with AZT monotherapy [106], or AZT/DDI [125], AZT/ddC or AZT/3TC [126]
dual therapy. These treatments had a modest effect in decreasing mortality and could only
partially achieve viral suppression. In 1996, a new form of therapy against HIV-1 infection
was introduced [127, 128]. To distinguish from the early ART, this new form of therapy
was termed potent combination antiretroviral therapy (cART), or later on highly active
antiretroviral therapy (HAART). It combines 2 NRTIs plus a potent antiretroviral agent
from another drug class, usually a PI (initially non-boosted and after 2000 mostly boosted),
a NNRTI, or an integrase inhibitor (used increasingly since 2010) [53, 129, 130]. Today, it
is generally believed that HAART can stop viral replication in most patients completely,
although there have been ongoing discussions whether low level replication might occur in
some patients or in some tissues [131]. However, the lack of evolution under HAART and
the absence of increasing treatment failures and emergence of resistance at the population
level so far are arguments against ongoing low level replication [98, 132–134].
HAART has remained the gold standard of anti HIV-1 treatment since introduction in
1996. It was also proven in our cohort, the Swiss HIV Cohort Study (SHCS), that cART
is highly effective in achieving viral suppression and reducing HIV-related morbidity and
mortality dramatically [13].
3.4 Treatment policy
There has been a constant debate since introduction of antiretroviral therapy as when to
start a treatment. Since HIV-1 infection is a chronic disease and needs to be treated life-
long with currently available drugs, not only maximal viral suppression and preservation
of the immune system but also the quality of a patient life is of high importance regarding
the time of initiation of treatment. The optimal time to start cART depends therefore on
the treatment benefits in balance with the downsides of long-term therapy such as drug
toxicity and potential emergence of viral drug resistance.
Before 2008, it had been constantly recommended that all HIV-1 infected patients with
HIV-related symptoms and all asymptomatic HIV-1 infected persons with CD4 cell count
≤ 200/µ` should be treated [135]. The recommendation in 2008 for treatment initia-
tion from the international AIDS society-USA panel lifted the treatment threshold to
CD4 counts < 350/µ` for all asymptomatic HIV-1 infected patients [136] because stud-
ies were published supporting benefits of treating patients at CD4 cell levels of 350/µ`
or above [137–140] without increasing the risks for adverse events caused by drug toxic-
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ity [141]. Moreover, newer medications are more potent and less toxic [142, 143], resulting
in reduced worries of substantial toxicity.
The latest treatment guideline in 2014 recommends treating all HIV-1 infected patients
regardless of their CD4 count. Benefits of early successful viral suppression outweigh the
potential toxicity that has become manageable with newer drugs. Two major effects can
be achieved if patients are treated early. On the individual level, a high CD4 count is
associated with better survival in general in HIV-infected patients. On the population
level, HIV-1 transmission can be strongly reduced because if viral load is suppressed an
HIV-1 infected individual is not infectious anymore [45, 144, 145]. Of course most impor-
tantly, the patients’ willingness to adhere to treatment is the prerequisite for any successful
antiretroviral treatment [136].
3.5 Treatment efficacy
Overall, given the number of antiretroviral agents and different drug classes available today,
most patients, including those having failed treatments and even carrying multiclass drug
resistance, can still successfully achieve viral suppression [53]. However, treatment efficacy
can be violated if drug concentration drops below the effective level. This is usually
influenced by non-adherence, including missing or delaying a dosage, or drug interactions
with another antiretroviral agent or other drugs [146]. For checking drug interactions
a comprehensive database can be found at: http://www.hiv-druginteractions.org/.
Clinicians familiar with antiretroviral therapy generally pay attention to this matter and
try to avoid possible drug-drug interactions before subscribing a treatment. For adherence
issues, several studies have focused on understanding the changing behavior of adherence
for possible future prevention [147–150]. One of the predictors for suboptimal adherence is
higher pill burden. Recently, a meta-analysis has demonstrated an association of lower pill
burden with better adherence [151]. On the other hand, due to the upcoming availability
of generic drugs it is possible that insurance companies and third-party payers are more
willing to pay for generic drugs because they cost less than co-formulations. One line of my
research focused on comparing the relative efficacy of four mostly used NRTI backbones
over time while taking into account the different number of pills (see Research Project 3
[Chapter 10] for more on this topic).

4
HIV-1 Drug Resistance
One of the major concerns of treating any infection is the emergence of drug resistance
against the antimicrobial agents used (true for bacteria, mycobacteria, parasites, fungal
and viral infections). In vitro and in vivo drug resistance was selected against all
available antiretroviral drugs developed for treating HIV-1 [152]. Although more than
25 antiretroviral agents are available for treating HIV-1 infection, broad cross-resistance
within drug classes and low genetic barriers of many drugs may decrease options for
subsequent treatments considerably.
The genetic barrier is defined as the number of mutations a virus needs to accumulate
to become resistant to a given antiretroviral drug. For example, EFV from the NNRTI
class has a low genetic barrier because the virus only requires one amino acid mutation
(e.g. the K103N) to confer full resistance to the drug. On the contrary, an antiretroviral
agent of high genetic barrier would not lose its activity until multiple mutations have
been accumulated, e.g., the boosted protease inhibitors.
Unfortunately, many agents with low genetic barriers also select for mutations that confer
broad cross-resistance, i.e., resistance mutations acquired from an agent confers resistance
against other agents. Key mutations such as K103N and Y181C alone can already lead
to inactivity of almost all NNRTIs [153]. Among NRTIs, a number of different mutations
are often selected upon failure and cause loss of activity to many other NRTIs [153, 154].
Compared to NRTIs and NNRTIs, boosted PIs (PI/r) have higher genetic barriers [155]
and so does the newest integrase inhibitor dolutegravir [156, 157]. Even with long exposure
to failing cART, PI/r containing regimens induce lower frequencies of PI mutations and
also prevent NRTI resistance when compared to NNRTI containing regimens [158].
On the other hand, some drug resistant mutations do not always decrease the sus-
ceptibility of a virus to all drugs; some mutations even increase the susceptibility to
other drugs. M184V is an example: M184V can be selected by ABC, FTC, or 3TC
but at the same time increases the susceptibility to AZT, TDF, and d4T [159–163].
There are several web resources for defining resistance mutations and predicting drug
susceptibility based on expert opinions. Among others, the Stanford drug resistance
database (http://sierra2.stanford.edu/sierra/servlet/JSierra) provides useful
online tools for genotype resistance interpretation using their own algorithm, based on
published phenotypic studies and repeated testing. The Stanford resistance interpretation
tool gives a penalty score for submitted sequences to predict the drug susceptibility
with given mutations. In addition to the Stanford algorithm, other genotypic resistance
interpretation systems have also been widely accepted and used: for example from
the Rega institute (http://rega.kuleuven.be/cev/) and from the Agence Nationale
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de Recherches sur le SIDA (ANRS; http://www.medpocket.com/) [164]. Advanced
statistical models and machine-learning algorithms based on data retrieved from viral se-
quences and phenotypic assays are also being developed to predict treatment failures [165].
4.1 Genetic variability
Due to the nature of an error-prone reverse transcriptase, it is estimated that the mutation
rate of HIV is 1.4-3 x 10−5 mutations/bp/cycle [166, 167]. Given that the HIV genome
is ≈ 10000 bp, one mutation is synthesized in every 10 replication cycles. This is within
the average range of the retroviral mutation rate. However, as pointed out by Coffin et
al. [168], the genetic diversity of HIV-1 in patients is not only owing to errors made during
the viral replication but also to the high rate of viral replication and the high viral load.
Given that an average HIV plasma viral load in an untreated patient is ≈ 105/m`, every
day ≈ 1010 virions are estimated to be produced [167, 169, 170]. These factors combined
with recombination, which can occur when a cell is co-infected with two or more divergent
HIV strains, lead to a high diversity of HIV variants [171, 172]. In theory, every position
of the HIV genome in an individual can be mutated every day [168, 173]. This means
that variants harboring drug resistant mutations are constantly generated also in the
absence of drugs. Among the large number of variants generated per day, many variants
with lethal mutations simply die out soon after being produced. Those variants that can
replicate in the normal host environment, i.e., in the absence of the selection pressure
of antiretroviral drugs, are called the wild type, to distinguish them from other variants
harboring mutations that confer drug resistance.
4.2 Selection of drug resistance
In the case of HIV, drug-resistant variants are selected by drug pressure exerted by an-
tiretroviral drugs. In other words, drug-resistant mutants are more fit in the environment
with drug pressure when compared to wild type variants. The drug-resistant mutants
usually harbor mutations that contribute to modifications on important drug targeted
enzymes such as reverse transcriptase, protease, and integrase to bypass the antiretroviral
activity of a drug, which enables them to continue to replicate under drug pressure. Due to
the high turn over rate of HIV, drug-resistant variants can outgrow wild type populations
quickly and become the majority in the quasispecies within days to weeks [170, 174, 175].
The reason for the selection of specific variants in a given environment is that some variants
have the ability to replicate more effectively than others, a property named fitness [38].
For example, mutations conferring resistance to NRTIs allow viruses to replicate in the
presence of NRTIs, but without such drugs these mutations actually decrease the viral
replication capacity. In other words, mutations can come with a fitness cost. Fitness cost
of a specific mutation or of a combination of mutations vary, depending largely on the
viral genetic background modulated by compensatory mutations [176–178].
In Research Project 2 (Chapter 9), the reversion rates and fitness costs of various trans-
mitted drug resistance mutations were studied in detail in vivo.
As mentioned before, factors required for creating variations including mutations are: high
replication rate, high error rate, high viral load, and recombination [168, 179, 180]. As a
result, drug resistance will rarely emerge if one of the factors is missing. When viremia
is controlled and suppressed by therapy, the virus does not replicate and thus no viral
evolution is occurring. Thus, in this perfect setting there is hardly any chance for drug
4.3. MECHANISMS OF DRUG RESISTANCE 27
resistance to emerge. Unfortunately, such a condition is usually not achieved in resource-
limited settings for a large fraction of patients. Due to non-adherence, drug shortage, and
lack of monitoring, drug resistance continues to emerge in these settings.
4.3 Mechanisms of drug resistance
In this section the resistance mechanism of the major three drug classes is summarized.
NRTI resistance includes two mechanisms: 1) the removal of the incorporated NRTI, and
2) the prevention of the incorporation of NRTI due to increased discrimination between
natural nucleotides and nucleos(t)ide analogues.
The first mechanism is related to thymidine analogue mutations (TAMs; TAM 1 includes
M41L, L210W, and T215Y, and TAM 2 includes D67N, K70R, T215F, and K219Q/E) and
is involved in the ATP-mediated removal of AZT [181–184], d4t and ddI [185, 186] from
the 3’ end of the DNA chain. ATP, which is abundant in lymphocytes, does not participate
in the process of DNA polymerization generally, but TAMs cause a conformational change
of reverse transcriptase, leading it to be able to bind ATP [187, 188]. ATP can thus
attack the bond between NRTI and DNA and facilitate the removal of NRTI. The second
mechanism that prevents NRTI from incorporating into the DNA chain is mediated by
mutations such as M184V/I, Q151M, and K65R. This group of mutations cause changes
to the reverse transcriptase so that the ability to incorporate NRTIs instead of natural
nucleotides is decreased [189]. The mutation M184V/I is selected by 3TC and FTC, and
less frequently by ABC. The position 184 is located in the middle of the catalytic site of
the reverse transcriptase [190], and the replacement of a methionine by a valine perturbs
the binding to 3TC, FTC, or ABC, resulting in the inhibition of those drugs. On the other
hand, it was shown that mutation M184V in the presence of ATP decreases the ability
to remove AZT [191]. Q151M is actually a group of mutations with Q151M being always
the first one to emerge in the group, and is also called the 151 complex. This pathway
starts with the substitution at the position 151 and is followed gradually by secondary
mutations (among others the A62V, V75I, F77L, F116Y) [192]. The 151 complex affects
all NRTIs currently approved except tenofovir [193, 194]. The mutation K65R is located
in the nucleotide-binding pocket and perturbs the binding activity to most NRTIs except
AZT [195].
Resistance mutations to NNRTI are all located in the catalytic binding site targeted
by NNRTIs and reduce the affinity of NNRTIs to the reverse transcriptase [196, 197].
Although this drug class is affected strongly by cross-resistance between different agents,
the most possible selection of a point mutation is dependent on the drug. For example, the
mutation Y181C is often associated with the use of NVP [198], and the K103N mutation
is mostly seen in patients failing EFV containing regimens [199]. Etravirine, being the 2nd
generation of NNRTI, is fully active against viral isolates harboring the K103N mutation.
However, activity vanishes rapidly if other NNRTI associated resistance mutations are
present [152]. Rilpivirene is the latest NNRTI and shows cross-resistance to almost all
major NNRTI mutations [152].
For PI resistance, primary mutations (also called major mutations) often emerge first,
followed by accumulation of secondary mutations (or minor mutations) [200, 201], which
are often already present as polymorphisms regardless of therapy. The presence of a large
number of polymorphisms is a specific feature of the protease gene; however, it was shown
that these polymorphisms are not relevant for treatment failure in patients starting PI
based regimens in subtype B infected patients [202]. Primary PI mutations are located
near the enzyme’s binding site, which is the same site binding both inhibitors and the
natural protease substrate, Gag and Gag-Pol polyproteins. Thus, PI resistance distorting
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the domain flexibility of the binding site reduces not only the binding to inhibitors but
also the natural substrates, and so reduces the viral replication fitness [203]. With time
the virus generates and selects minor mutations that directly compensate for the viral
fitness reduced by major mutations [177, 204, 205]. After the accumulation of secondary
mutations, further mutations can be selected to create a novel Gag-Pol frame shift site,
resulting in more Gag-Pol polyproteins being produced [206]. This further compensates
the reduced fitness caused by major mutations. Taken together, HIV utilizes this step-
wise mutation pathway to escape from the PIs and at the same time to restore the viral
fitness [204].
4.4 Acquired drug resistance
If drug-resistant variants did not exist in a patient at the time when this person was
infected and were selected during the course of treatment through the exerted drug
pressure, this kind of drug resistance is referred to as acquired drug resistance. As the
name suggests, the resistance in general is acquired on a failing, or not fully active,
treatment.
When treatment is discontinued, the selection pressure of drugs disappears gradually
depending on the half-life of the drugs. The different half-lives play an important role
for emergence of acquired drug resistance when stopping therapy. For example, EFV or
NVP usually have long half-lives compared with most NRTIs. If all drugs in a regimen
containing NNRTI and NRTIs are stopped at the same time, levels of NNRTI last longer
than NRTIs leaving a period of monotherapy with functional NNRTI only. This may
select NNRTI resistance [207]. After discontinuation of therapy, the virus with detectable
drug resistance can soon become susceptible again [99, 208] because the wild type viral
strain that circulated before the initiation of the therapy has been archived in the latent
reservoir (see Chapter 2.3 for latency) [85, 97, 209, 210], and becomes again the fittest
variant in the quacispecies. The reversion rate of a drug resistance mutation also depends
on the differential fitness costs of mutations [211]. In general, we define reversion of a
mutation as decreasing to below the detection limit of population sequencing, which has
changed over time (from the initial detection limit of 400 copies/m` to 50 copies/m`, and
now to 20 copies/m`).
A persisting or a relapsing HIV viral load in a treated patient is an indicator for treatment
failure and often resistance emerges in those patients. To test which drug resistance
mutations have been acquired, one needs to perform resistance testing. It remains a
challenge to appropriately interpret results of resistance testing. Predefined lists are
created for this purpose, and I consulted the IAS-USA surveillance list for defining
acquired drug resistance mutations [152, 193]. More details about resistance testing are
given in Chapter 4.6.
4.5 Transmitted drug resistance
Patients on a failing treatment are potentially infectious with drug-resistant viruses. If
such patients infect other healthy individuals or in rare cases also superinfect an already
HIV-infected individual [212], the newly infected patient will unavoidably carry the drug-
resistant viruses without ever having been exposed to antiretroviral treatment. This kind
of resistance is then referred to as transmitted drug resistance.
Transmitted drug resistance in most cases is carried by treatment-na¨ıve individuals. As
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opposed to acquired drug resistance, transmitted drug resistance can persist longer in
an environment without drug pressure, due to the fact that in 60-90% of cases only one
variant from a transmitter is transmitted [45, 46] and thus in those being infected with a
drug-resistant variant, the drug-susceptible wild type is not transmitted to the recipient
and cannot be archived in the latent reservoir. To acquire the wild type variant, the
virus needs to mutate at the amino acid position associated with drug resistance. It
is generally assumed that the wild type emerges at a different pace depending on the
fitness cost that the mutation is associated with [146]. It will do so rapidly only if a
fitness benefit occurs with reversion of drug resistance mutations. Previous findings have
shown that the differential persistence time of transmitted drug resistance mutations vary
considerably [213–215]. Moreover, after reversion, transmitted drug resistance mutations
persist as a minority [216] and can jeopardize the first-line treatment efficacy [174, 217–
219]. It has also been unambiguously shown by our group [220] that minority variants
carrying drug resistant mutations can be transmitted, but to date it remains controversial
how important these minority variants are for treatment success [217, 221, 222]. They are
most likely not relevant for high genetic barrier drug treatment [216].
I have studied in detail the relationship of reversion with fitness cost of a mutation in
Research Project 2 (Chapter 9), and the prevalence of transmitted drug resistance in
Research Project 1 (Chapter 8). For my projects about TDR, I consulted the WHO
surveillance list for transmitted drug resistance to define mutations [223, 224].
4.6 Resistance testing
To test if a patient harbors drug resistance it is necessary to perform resistance test-
ing at several time points. Today guidelines [146] recommend resistance testing for both
treatment-na¨ıve patients and treatment-experienced patients. To identify whether a newly
infected patient harbors transmitted drug resistance, all treatment-na¨ıve patients are rec-
ommended to have resistance test at entry into care regardless of whether cART will be
initiated immediately or not [146]. The idea of early resistance testing is to identify as many
resistance mutations as possible including the fast-reverting mutations such as M184V and
K65R [214, 225, 226] to prevent early treatment failure [174, 216]. When changing a reg-
imen, resistance tests can assist the selection of subsequent drug regimens. Therefore, it
is especially recommended to perform a resistance test at the time of changing a regimen
in patients changing due to treatment failure. For patients on treatment whose viral load
cannot be suppressed, it is also recommended to test resistance to manage suboptimal
viral load reduction [146].
There are two types of assays to test drug resistance: phenotypic and genotypic assays.
The tested gene of interest is the gene that the drug exerts selection pressure on, e.g. part
of the pol gene for PIs, NRTIs, NNRTIs, and integrase inhibitors, and part of the env gene
for Maraviroc, etc.
4.6.1 Genotypic resistance test
The genotypic resistance assays sequence viral genes using population sequencing tech-
niques and predict the virus’s susceptibility of antiretroviral drugs based on predefined
master lists [152, 193, 224] or rule-based algorithms [164]. Due to the low cost and short
performance time, genotypic testing is preferred for routine clinical practice.
Since genotypic resistance testing requires expert interpretations of the results, the major
limitation of it is to correctly predefine mutations. This can be challenging because
the impact of different mutations on drug susceptibility varies largely. Predictions of
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available algorithms are not always in agreement, which makes interpretation of genotypic
resistance tests sometimes difficult [146, 227].
4.6.2 Phenotypic resistance test
Phenotypic testing today mostly uses recombinant virus assays based on the construction
of a reference HIV vector with inserted genes of patiens’ viruses. Theses recombinant
viruses are cultured in the presence of a single drug at different concentrations. The fold-
change of the amount of drug needed to inhibit viral replication by 50% (called the half
maximum inhibitory concentration (IC50)) is measured. Phenotypic assays can yield direct
results for patients individually, and no predefined master lists for testing interpretation
are needed [146, 227]. However, to perform phenotypic testing it takes more time and
more money compared to genotypic testing. In addition, comparative clinical studies have
never shown superiority of phenotypic assays over genotypic tests [228, 229]. Therefore,
phenotypic resistance tests are mainly used for studying emergence of resistance against
new drugs in vitro and in the first clinical studies.
4.7 Resistance prevalence
Drug resistance can be found in every country where antiretroviral drugs are available.
The continuing evolution of drug resistance in circulating HIV variants presents a global
challenge.
In resource-rich countries, drug resistance is mostly under control. Prevalence of acquired
drug resistance has declined dramatically due to successful treatments and regular mon-
itoring [132, 230], and prevalence of transmitted drug resistance has remained stable, at
around 8% to 10%, over time [31, 231–234]. Among drug classes, transmitted NRTI re-
sistance has the highest prevalence, which has been stable or even decreasing over time.
On the contrary, transmitted NNRTI resistance has the lowest prevalence compared to
NRTIs and PIs but has risen in the past years [235]. Two conclusions can be drawn here.
On the one hand, the different time trends between drug classes suggest that prevalence
of transmitted drug resistance is associated with the roll-out time of antiretroviral drugs.
NNRTI being the last to be introduced among the three major drug classes expectedly
has the lowest prevalence that is increasing, but eventually the increase will stop as seen
in the prevalence of transmitted NRTI resistance and it was predicted by mathematical
modeling by Blower et al. that prevalence of transmitted drug resistance will remain low
because its increase reaches a plateau [236]. On the other hand, if drug resistance is pri-
marily transmitted by treatment-failing patients as generally hypothesized, the constant
decrease of the rate of acquired drug resistance and the stable, or in some countries the
increasing, trend of the rate of transmitted drug resistance together present a paradox.
To further assess this paradox was exactly the aim of my Research Project 1 (Chapter 8).
For resource-limited countries, situations are different. Although prevalence of transmitted
drug resistance is lower in resource-limited countries [237, 238], it was found to have in-
creased substantially since the roll-out of antiretroviral drugs in individual countries [239–
241]. Two potential dangers exist. First, rising prevalence of transmitted drug resistance
could increase both numbers of early first-line treatment failures [218] and prevalence of
multiclass resistance. Since drug options are limited in these settings and viral load mon-
itoring is still the exception, controlling the epidemic there could presumably become a
problem in the long term. Secondly, since in high-income countries there is a lot of trav-
eling to resource-limited countries (e.g., business, vacation, sex tourism) and immigration
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from resource-limited countries, in particular to Europe, are strongly increasing, more
new infections harboring transmitted drug resistance might be expected in high-income
countries in the long run.
In conclusion, drug resistance still represents a global concern. To develop a timely strat-
egy to restrain both acquired drug resistance and the transmitted drug resistance, which
has earned rising attention, one needs to first understand the mechanism of how drug
resistance spreads.

5
The Swiss HIV Cohort Study (SHCS) and Databases
All my research projects are based on information stored either in the Swiss HIV Cohort
Study (SHCS) database or the SHCS drug resistance database.
5.1 The SHCS
The SHCS (www.shcs.ch) is a prospective and nationwide cohort study including a
large biobank consisting of plasma and liquid nitrogen frozen cells. It continuously
enrolls patients of all transmission groups aged 16 or older since 1988. The study is a
collaboration of seven large medical centers (including all 5 Swiss University hospitals):
Basel, Bern, Geneva, Lausanne, Lugano, St. Gallen, and Zurich. In addition, smaller
regional hospitals and private physicians carrying for HIV patients are associated with
the large centers. The SHCS has been approved by ethical committees of all participating
institutions. Written informed consent was obtained from all patients. Basic information
of patients such as gender, birth, and ethnicity are collected at registration [10, 242],
and clinical data such as CD4 count and HIV-RNA viral load are collected every six
months at each visit. In addition, detailed treatment history including product name and
dosage is documented, and a systematic questionnaire is conducted addressing, e.g., drug
adherence, toxicity, living conditions, and sexual behavior.
The SHCS is representative for the HIV epidemic in Switzerland. The SHCS includes
at least 53% of all HIV cases ever diagnosed, 72% of all patients receiving ART, and
69% of the nationwide registered AIDS cases in Switzerland [242]. In fact, these numbers
are based on a conservative estimate. For example, the Swiss Federal Office of Public
Health (FOPH) estimated that around 500 - 1000 people were newly diagnosed with a
HIV-1 infection each year from 1996 to 2012, resulting in 11870 cases in total. This was
in approximate accordance to the number of participants enrolled into the SHCS during
the same time period (n=10050 from 1996-2012; Figure 5.1). Thus, from 1996 onward to
at least 2012, the coverage of the SHCS for the Swiss epidemic is ≈ 85%.
Up to February 2015, the SHCS has enrolled 18734 patients and ≈ 81% of patients have
received treatment.
5.1.1 The Zurich Primary HIV Infection (ZPHI) Study
The Zurich Primary HIV infection study (ZPHI:http://www.viralinfectiousdiseases.
uzh.ch/ZPHI.html) was initiated in 2002. Since 2012, the ZPHI belongs to the Clinical
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Figure 5.1: Representativeness of the SHCS
Research Priority Program (CRPP) Viral Infectious Diseases, which is a research project
funded by the University of Zurich. The ZPHI enrolls patients with primay HIV-1 infec-
tion. Most of the patients are also enrolled in the SHCS. The focus of ZPHI is to explore
new treatment strategies in HIV-1 primary infected patients.
5.2 The SHCS drug resistance database
The SHCS drug resistance database collects all genotypic resistance tests performed for
SHCS patients in clinical routine and for research purposes. Four laboratories in Switzer-
land are authorized by the Federal Office of Public Health to perform these tests. All
laboratories perform population-based sequencing of the full protease gene and at least
codons 28-225 of the reverse transcriptase gene using either in-house methods [243] or
commercial assays (Viroseq Vs.1 PE Biosystems; Virsoseq Vs.2, Abbott AG; VircoTYPE
HIV-1 Assay, Virco Lab). In addition, all laboratories have participated in the annual
quality control evaluation by the Agence Nationale de la Recherche du SIDA (ANRS)
since 2002. All sequences are entered into the SHCS drug resistance database using
SmartGene’s Integrated Dababase Network System (SmartGene, Zug, Switzerland, IDNS
version 3.6.3) [244]. A large part of sequences generated retrospectively was selected for
my PhD work (for more detail see Chapter 7). In addition to resistance mutation data
and all essential test information such as sequence identifier and sequence date, subtypes
are also stored in the database. Subtyping is performed on the protease and the reverse
transcriptase sequence using REGA 2 (http://jose.med.kuleuven.be/genotypetool/
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html/subtypinghiv.html). If it returns inconclusive results, the analysis is repeated with
the Star analyzer (http://www.vgb.ucl.ac.uk/starn.shtml) [245].
Up to June 2014, there were 9764 sequences from 4932 treatment-experienced patients
and 10680 sequences from 8089 treatment-nave patients stored in the database.

6
Thesis Objectives
My research focused on several aspects that are fundamental to achieving treatment suc-
cess. In the first project I studied the paradox between the prevalence of acquired and
transmitted drug resistance as well as time trends of prevalence and associated risk fac-
tors. In the second project I analyzed the time needed for reversion of transmitted drug
resistance mutations and its association with the fitness cost of mutations. In the third
project I compared the efficacy of four most used and recommended NRTI combinations
in a NNRTI backbone taking into account the different numbers of pills and dosing fre-
quencies of the regimens.
The aim of these projects was to provide additional helpful information to better under-
stand the interplay between transmitted and acquired drug resistance on the population
level and to help to improve the outcome of antiretroviral treatment in the long run.
Furthermore, I believe that my results will also be of value for public health policies in
Switzerland and abroad.
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7
Sample Selection for Retrospective Sequencing
The SHCS resistance database consists of genotypic resistance tests performed for both
clinical routine and research purposes. Most tests for research purposes were performed
retrospectively, especially for patient plasma samples originating from before 2002 when
genotyping was not yet integrated into routine clinical care.
An essential amount of time for this PhD thesis was dedicated to systematically identify
plasma samples according to a variety of criteria for retrospective sequencing. Samples
were retrieved from separate freezers located in seven clinical centers throughout Switzer-
land and sent to the sequencing laboratories of the Institute of Medical Virology, University
of Zurich, and Laboratory of Virology, Geneva University Hospital. In total, 5464 samples
were found to complement the SHCS resistance database in the following ways:
1. to have a baseline sequence for every treatment-na¨ıve patient (n=1530 for this pur-
pose)
2. to have sequential sequences from every treatment-na¨ıve patient carrying transmitted
drug resistance before starting treatment (n=944)
3. to have a genotyped sequence for every failed treatment per patient (n=2017)
4. to have an integrase sequence for treatment-na¨ıve patients registered after Jan. 1,
2009 and treatment-failing patients who have failed for the first time after Jan. 1,
2009 (n=819)
5. to study subtype evolution until undergoing treatment, i.e., to have sequential se-
quences from patients infected with one of the most frequent subtypes in the SHCS:
B, A, C, AE, AG (n=990)
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Assessing the Paradox Between Transmitted and Acquired
HIV-1 Drug Resistance in the Swiss HIV Cohort Study From
1998 to 2012
Published by J Infect Dis. (2015) doi: 10.1093/infdis/jiv012
Personal Contributions
For this study I systematically selected patient plasma samples for retrospective sequenc-
ing. First, I looked for patients without a baseline genotypic sequence while being
treatment-na¨ıve and patients failing a treatment who had not been sequenced. Subse-
quently, I searched in the SHCS database if these patients have suitable and available
plasma samples stored in the SHCS biobank. If yes, I requested them to be retrieved
and retrospectively sequenced. I combined the genotyping information from the SHCS
resistance database with the treatment information from the SHCS databases, selected
patients that matched the criteria of our study aim and documented every inclusion and
exclusion step including reasons and numbers yielded. I did all statistical analyses. I
generated and designed all figures and tables. Finally, I wrote the first version of the
manuscript and edited it after comments of the co-authors.
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Abstract
Background
Transmitted HIV-1 drug-resistance mutations (TDR) are transmitted from treatment-
failing or treatment-na¨ıve patients. Although prevalence of drug-resistance in treatment-
failing patients has declined in developed countries, TDR prevalence has not. Mechanisms
causing this paradox are poorly explored.
Methods
We included recently-infected, treatment-na¨ıve patients with genotypic-resistance-tests
performed ≤ 1 year post-infection and < 2013. Potential risk factors for TDR were an-
alyzed using logistic regression. Association of TDR prevalences with population viral
load(PVL) from treatment-patients during 1997 - 2011 was estimated with Poisson re-
gression for all TDR and individually for most frequent resistance-mutations against each
drug class (M184V/L90M/K103N).
Results
We included 2421 recently-infected, treatment-na¨ıve patients and 5399 treatment-failing
patients. TDR prevalence fluctuated considerably over time. Two opposing developments
could explain these fluctuations: generally continuous increases in TDR (Odds Ratio [OR]
= 1.13, p = 0.010), punctuated by sharp decreases when new drug-classes were introduced.
Overall, TDR prevalence increased with decreasing PVL (Rate Ratio[RR] = 0.91 per 1000
increase in PVL, p = 0.033). Additionally, we observed that the transmitted high-fitness-
cost mutation M184V was positively associated with PVL of treatment-failing patients
carrying M184V (RR = 1.50 per 100 increase in PVL, p < 0.001). Such association was
absent and negative for K103N (RR-K103N = 1.00 per 100 increase in PVL, p = 0.99)
and L90M (RR-L90M = 0.75 per 100 increase in PVL, p = 0.022), respectively.
Conclusions
Transmission of antiretroviral drug-resistance is temporarily reduced by the introduction
of new drug classes and driven by treatment-failing and treatment-na¨ıve patients. These
findings suggest a continuous need for new drugs, early detection and early treatment of
HIV-1-infection.
M A J O R A R T I C L E
Assessing the Paradox Between Transmitted
and Acquired HIV Type 1 Drug Resistance
Mutations in the Swiss HIV Cohort Study From
1998 to 2012
Wan-Lin Yang,1 Roger Kouyos,1 Alexandra U. Scherrer,1 Jürg Böni,2 Cyril Shah,2 Sabine Yerly,4 Thomas Klimkait,5
Vincent Aubert,7 Hansjakob Furrer,9 Manuel Battegay,6 Matthias Cavassini,8 Enos Bernasconi,10 Pietro Vernazza,11
Leonhard Held,3 Bruno Ledergerber,1 and Huldrych F. Günthard1; and the Swiss HIV Cohort Studya
1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 2Swiss National Center for Retroviruses, Institute of Medical
Virology, and 3Institute of Social and Preventive Medicine, University of Zurich, 4Laboratory of Virology, Division of Infectious Diseases, Geneva University
Hospital, 5Department of Biomedicine-Petersplatz, University of Basel, 6Division of Infectious Diseases and Hospital Epidemiology, University Hospital
Basel, 7Division of Immunology and Allergy, and 8Division of Infectious Diseases, University Hospital Lausanne, 9Department of Infectious Diseases, Berne
University Hospital and University of Berne, 10Division of Infectious Diseases, Regional Hospital Lugano, and 11Division of Infectious Diseases, Cantonal
Hospital St. Gallen, Switzerland
Background. Transmitted human immunodeﬁciency virus type 1 (HIV) drug resistance (TDR) mutations are
transmitted from nonresponding patients (deﬁned as patients with no initial response to treatment and those with
an initial response for whom treatment later failed) or from patients who are naive to treatment. Although the prev-
alence of drug resistance in patients who are not responding to treatment has declined in developed countries, the
prevalence of TDR mutations has not. Mechanisms causing this paradox are poorly explored.
Methods. We included recently infected, treatment-naive patients with genotypic resistance tests performed ≤1
year after infection and before 2013. Potential risk factors for TDR mutations were analyzed using logistic regression.
The association between the prevalence of TDR mutations and population viral load (PVL) among treated patients
during 1997–2011 was estimated with Poisson regression for all TDR mutations and individually for the most frequent
resistance mutations against each drug class (ie, M184V/L90M/K103N).
Results. We included 2421 recently infected, treatment-naive patients and 5399 patients with no response to treat-
ment. The prevalence of TDR mutations ﬂuctuated considerably over time. Two opposing developments could explain
these ﬂuctuations: generally continuous increases in the prevalence of TDRmutations (odds ratio, 1.13; P = .010), punc-
tuated by sharp decreases in the prevalence when new drug classes were introduced. Overall, the prevalence of TDR
mutations increased with decreasing PVL (rate ratio [RR], 0.91 per 1000 decrease in PVL; P = .033). Additionally, we
observed that the transmitted high-ﬁtness-cost mutation M184V was positively associated with the PVL of nonres-
ponding patients carrying M184V (RR, 1.50 per 100 increase in PVL; P < .001). Such association was absent for
K103N (RR, 1.00 per 100 increase in PVL; P = .99) and negative for L90M (RR, 0.75 per 100 increase in PVL; P = .022).
Conclusions. Transmission of antiretroviral drug resistance is temporarily reduced by the introduction of new drug
classes and driven by nonresponding and treatment-naive patients. These ﬁndings suggest a continuous need for new
drugs, early detection/treatment of HIV-1 infection.
Keywords. HIV; transmission; drug resistance; recently infected; ﬁtness.
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8.1 Introduction
Transmission of HIV-1 infection depends strongly on individual levels of plasma
viremia [246]. When HIV-1-infected patients receive suboptimal treatment or incom-
plete adherence to anti-retroviral therapy (ART), drug-resistant viruses emerge and
continue replicating. Therefore, the general assumption is that drug-resistant viruses
are mainly transmitted from treated patients with high levels of HIV viremia due to
failed [Hirsch:1998wb]. Modern ART reduces the viremia levels and transmissibility of
HIV-1 more effectively than earlier ART [247], suggesting less emergence [133] and trans-
mission of HIV-1 drug-resistance over time.
In recent years, the incidence and prevalence of acquired drug-resistance mutations (ADRs)
in treated patients has indeed declined due to effective ART in various developed coun-
tries [132, 230]. However, prevalence of transmitted drug-resistance mutations (TDR) has
often remained stable [231, 235, 248]. TDR may cause early virological failure when pa-
tients start their first-line therapy [218]. Certain TDR can persist for years in the absence
of drug pressure after seroconversion [214] and have long-term potential to jeopardize the
effectiveness of ART; other TDR may disappear rapidly and become undetectable via
population sequencing [214, 217]. Recently, transmission of minority variants harboring
drug-resistance has been demonstrated [220]. Difficulties in detecting TDR upon ART ini-
tiation might therefore compromise the treatment success achieved thus far.
In the current study we aimed at analysing the risk factors of TDR, and resolving the
discrepant patterns of TDR and ADR prevalence over time. The unique SHCS dataset,
which is representative for ≥ 15 years, allows us to determine the impact of temporarily
changing factors such as numbers of available drug classes. We adapted population viral
load (PVL) as a tool to assess the spread of drug-resistance and the transmission potential
of the treatment-experienced population. We focused specifically on TDR during recent
infections to avoid potential bias caused by different TDR persistence times.
8.2 Methods
Study population
The SHCS, enrolling patients since 1988, is a prospective, nationwide, clinic-based
study including a biobank. The SHCS is representative for the HIV epidemiology
in Switzerland; it includes at least 53% of all HIV cases ever diagnosed in Switzer-
land, 72% of all patients receiving ART, and 69% of the nationwide registered AIDS
cases [242]. Additionally, we enrolled patients from the Zurich Primary HIV-infection
study (ZPHI:www.clinicaltrials.gov; ID=NCT00537966) which focuses on identifying
and treating patients during early infection [46]. Ethical approval from all participating
institutions and written informed consent from all patients was obtained [10, 46, 242].
To identify the TDR prevalence, we included recently-infected, treatment-na¨ıve patients
(definition: see below) with a genotypic resistance test (GRT) performed before 1.1.2013.
The first GRT from each recently-infected, treatment-na¨ıve individual was considered. All
sequences before 1996 were grouped as ≤ 1995 because of small sample sizes. For the asso-
ciation analysis, in which we tested whether TDR prevalence is associated with the PVL
from ART-failing patients, we included ART-failing patients from 1997 - 2011 due to the
representative availability of VL testing since 1997.
GRTs stem from routine-clinical testing performed by four laboratories in Switzerland
authorized by the Federal Office of Public Health. All laboratories perform population-
based sequencing of the full protease gene and at least codons 28 - 225 of the reverse
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transcriptase gene using commercial assays (Viroseq Vs.1 PE Biosystems;Virsoseq Vs. 2,
Abbott AG; vircoTYPE HIV-1 Assay, Virco Lab) and in-house methods [243] and par-
ticipate in the yearly quality control evaluation by the Agence Nationale de la Recherche
du SIDA (ANRS) since 2002. All sequences are entered into the SHCS drug-resistance
database using SmartGene’s Integrated Dababase Network System (SmartGene, Zug,
Switzerland, IDNS version 3.6.3) [244]. Additionally, we performed systematically ret-
rospective sequencing for blood samples that were stored in the biobank before routine
genotyping was introduced (over 11000 sequences were retrospectively generated). Sub-
typing was performed on the protease and the reverse transcriptase sequence using REGA
2 (http://jose.med.kuleuven.be/genotypetool/html/subtypinghiv.html). If this
method returned inconclusive results, the analysis was repeated with the Star analyzer
(http://www.vgb.ucl.ac.uk/starn.shtml) [245].
TDR were identified using the WHO list for surveillance of transmitted HIV drug-
resistance [224].
Definition of recent infection
To account for potential reversion of TDR in the absence of drug pres-
sure [Devereux:1999ua, 213, 214, 225, 249, 250], we restricted our study population to
treatment-na¨ıve patients having been diagnosed ≤ 1 year after infection. Specifically, we
determined recent infection with one of the following methods:
1. Documented acute HIV-1 infection as previously described [46].
2. Documented seroconversion (< 1 year between the last negative and first positive
HIV tests).
3. For those lacking the data mentioned above, the ambiguity score [49] was used. It is
a measure of the viral nucleotide diversity from bulk sequencing which estimates the
infection duration. Sequences with ≤ 0.5% ambiguous nucleotides were considered
to be GRTs from recently-infected patients [49]. However, as diversity may be low in
long-term HIV-infections, patients with a score ≤ 0.5% and a CD4 count < 200 were
excluded to reduce false positives. For validation of this method, see Supplementary
Material.
The viral burden of treatment-failing patients
PVL was used to describe the viral burden of ART-failing patients for the coming year
on a population level. We summed up the log10 transformed VLs from all ART-failing
patients of a given year. For further analyses, where we studied the transmission pattern
of a specific TDR, the total of log10 transformed VLs from ART-failing patients carrying
the corresponding mutation was used. Only VLs corresponding to a GRT were included
for these analyses because genotyping was needed to determine drug-resistance mutations.
To acquire all potential treatment failures, we defined treatment failure as having a VL ≥
400 copies/m` after 180 days of continuous ART. VL measurement was not fully integrated
into the clinical routine before 1997, so we included VLs from treatment-failing patients
during 1997 - 2011. Each person contributed to each year once. If a patient had ≥ 2 VLs
measured within the same year, we calculated the mean for that year.
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Statistical methods
Potential risk factors for acquiring any TDR were analyzed using logistic regression. Vari-
ables investigated were ethnicity (Caucasian, Black, others), gender (male, female), trans-
mission group (men having sex with men [MSM], heterosexual transmission [HSX], inject-
ing drug users [IDU], others), HIV-1 subtype (B, non-B), and the calendar year of sam-
pling (fitted as a continuous variable). Additionally, since we suspected that less optimal
regimens resulting from fewer choices of available drugs might have influenced TDR trans-
mission, we included the number of available drug classes as an ordered categorical variable
(the p-value was obtained from the test for trend). In Switzerland, HIV-1 treatment oc-
curred in five eras, each separated by the introduction of a new drug class: Mono-class
therapy with nucleoside analogue reverse transcriptase inhibitors (NRTI) was used before
1996 (1 drug class:≤ 1996). After the introduction of unboosted protease inhibitors (PI)
in 1996, patients could obtain dual-class regimens (2 classes:1997 - 1998). Subsequently,
non-nucleoside analogue reverse transcriptase inhibitors (NNRTI) were introduced in 1998
(3 classes:1999 - 2000), followed by boosted PI (PI/r) in 2000 (4 classes:2001 - 2008), and
integrase inhibitor (InSTI) in 2008 (5 classes:2009 - 2012). In the model we included binary
response indicating detection of any TDR from each patient as an outcome. We analyzed
variables independently and included those associated significantly with the outcome into
the multivariable model (HIV subtype and transmission group). We also chose variables a
priori regardless of univariable significance due to likely biological impacts (sex, year, and
number of available drug classes). For TDR to individual drug classes, we included the
same co-variables in the multivariable models for reasons of consistency to avoid obtaining
a different set of variables for each drug class. We found no collinearity and interactions
between any included variable. Missing data were list-wise deleted. We calculated odds
of TDR detection from our fitted multivariable model by retaining all co-variables except
for year and number of available drug classes at baseline, and transformed the predicted
odds to annual prevalences.
In the association analysis we applied Poisson regression to assess the association of TDR
transmission with treatment-failing patients as potential transmitters. We considered an-
nual rates of GRTs detecting TDR from recently-infected, treatment-na¨ıve patients as
outcome and PVL of all treatment-failing patients from the previous year as explanatory
variable. We further studied the association for the most prevalent drug-resistance mu-
tation for each major drug class in the SHCS: M184V, L90M, and K103N for NRTI, PI,
and NNRTI, respectively. In this individual-mutation analysis, we fitted the model with
the annual prevalence of each of these three transmitted mutations as outcome and the
PVL of ART-failing patients carrying the corresponding mutation from the previous year
as explanatory variable. We performed sensitivity analyses including PVL from the same
year of GRTs performed or from two years before (see Supplementary Material).
We expressed our results with 95% CI and two-sided p-values, with p < 0.05 being statis-
tically significant. Data analyses were performed with Stata 13.0 SE (StataCorp, Texas,
USA).
Subgroup analysis
Considering that transmission to some SHCS patients may have occurred abroad and that
the TDR prevalences of those patients would be less relevant to treatment-experienced
patients in Switzerland, we repeated the association analyses with only those patients
found in Swiss transmission clusters, defined phylogenetically [251]. To summarize, HIV-1
subtype B pol sequences from 8271 SHCS patients were pooled with foreign pol sequences
from the Los Alamos Sequence database (n = 36230). Clusters were defined as clades
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containing ≥ 10 sequences and consisting of ≥ 80% sequences from the SHCS.
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Figure 8.1: Fraction of positive GRTs detecting any drug-resistance mutation for acquired
and transmitted drug-resistance in the SHCS
20120 GRTs were generated in total before Jan.1, 2013 in the SHCS. 10504 GRTs (blue triangles) were
performed from 7920 patients when they were treatment-na¨ıve (regardless of recent infection), and 9616
GRTs (red dots) from 4816 individuals when they were treatment-experienced. Fractions of positive GRTs
detecting any drug-resistance mutation for both populations were shown. The annual numbers of included
GRTs from treatment-experienced (first row, red) and from treatment-na¨ıve (second row, blue) patients
were listed below the graph. Linear regression with fraction as dependent variable and year as explanatory
variable showed that the fraction of positive drug-resistance tests in treatment-experienced patients has
declined substantially over time (-2.8% per year [-3.4%, -2.2%]; p < 0.001), whereas the fraction of positive
drug-resistance tests in treatment-na¨ıve patients has not (0.3% per year [0.2%, 0.5%]; p < 0.001).
Vertical bars = 95% CI
8.3 Results
Fraction of positive GRTs in the SHCS
Figure 8.1 summarizes the fraction of TDR and ADR from all 20120 GRTs sampled
before Jan. 1, 2013 regardless of the infection duration stratified by treatment status
(na¨ıve/experienced). Specifically, 10504 GRTs were from 7920 treatment-na¨ıve and 9616
GRTs from 4816 treatment-experienced individuals.
ADR reached a peak at 85% in 1998 and dropped continuously since then to a plateau
at 38% in 2009. This strong decrease of fraction of positive GRTs for ADR (linear
regression: -2.8% / year [-3.4%, -2.2%]; p < 0.001) was not followed by a parallel decrease
but rather a slight increase of fraction of positive GRTs for TDR (0.3% / year [0.2%,0.5%];
p < 0.001). To further dissect this discrepancy and to avoid possible bias introduced by
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different persistence times of TDRs, we focused on studying treatment-na¨ıve patients with
GRTs performed within recent infection.
Study population including recently-infected, treatment-na¨ıve and
treatment-failing patients
We identified 2421 (31%) recently-infected patients from 7920 treatment-na¨ıve patients in
the SHCS with ≥ 1 GRT performed between June 26, 1992 and Dec.18, 2012. Additionally,
we included 5399 patients having failed ≥ 1 regimen within years 1997 - 2011, presenting
18097 yearly-unique VL measurements. For detailed patient selection, see Figure 8.2. For
representativeness of study population see Supplementary Figure S1.
TDR prevalences over time in recently-infected treatment-na¨ıve patients
and associated risk factors
TDR prevalences fluctuated substantially over time with the median (range) as follows:
9.1% (2.2%, 15.6%) to any drug; 5.8% (2.2%, 14.3%) to NRTI; 2.5% (0, 4.8%) to PI; 1.4%
(0, 5.1%) to NNRTI (Figure 8.3, black dots).
We observed two opposing developments in the multivariable logistic model that could
explain the complex fluctuations of TDR prevalences (Table 8.1). On the one hand,
overall TDR prevalence dropped after introduction of new drug classes. In particular,
prevalences of TDRs significantly dropped after PI/r and InSTI became available. On the
other hand, we found a linear increase of TDR prevalences when the number of available
drug classes remained constant (Figure 8.3). The combination of these two opposing
developments resulted in TDR prevalences, which increased in the absence of new drugs
but decreased sharply upon introduction of new drug classes. TDR prevalences predicted
from this model were shown in Figure 8.3 (blue lines). Additionally, prevalences of TDR
to individual drug classes showed similar but not significant patterns as mentioned above
(Supplementary Table S1.1-S1.3).
Association of drug-resistance transmission with the viral burden of
treatment-failing patients
We further investigated whether drug-resistance transmission was associated with
treatment-failing patients. We fitted annual prevalences of any TDR (outcome) and PVL
of treatment-failing patients from the previous year (explanatory variable) with a Poisson
regression model. The rate ratio (RR) was 0.91/1000 PVL (0.83, 0.99; p = 0.033), in-
dicating a 9% increase of TDR prevalence for a decrease of PVL of ART-failing patients
from the previous year by 1000 (Figure 8.4 A,E). PVL itself decreased over time (linear
regression: -318/year [-438, -197]; p < 0.001). When we considered patients identified in
Swiss transmission clusters, we found no discernible evidence for an association between
TDR and PVL (RR=0.76/1000 PVL [0.43, 1.34]; p = 0.34).
Taken together, our results suggested no or a negative association between TDR preva-
lences and PVL of ART-failing patients from the previous year.
Transmission of the class specific drug-resistance mutations M184V,
L90M, K103N
The above analysis pooled all TDRs and potentially neglected the differential behavior of
individual mutations. We therefore performed individual-mutation analysis for the most
prevalent drug-resistance mutation for each drug class.
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17835 patients enrolled in the SHCS before 1.1.2013
7920 having ≥1 GRT performed while treatment-naïve 
before 1.1.2013
9915 without GRTs from when treatment-
naïve before 1.1.2013
2914 recently-infected patients identified: 
254 enrolled in ZPHI
264 with a documented infection date
710 with a documented seroconversion
1686 with ambiguity ≤ 0.5%
5006 not identified as recently infected 
when GRT was performed.
2421 recently-infected treatment-naïve patients 
included
306 having low CD4 count (< 200/mm3) 
187 lacking of CD4 information
2355 included for the uni-/multivariable logistic regression (Table 2)
66 without a clearly-defined 
HIV-1 subtype
252 had no GRT performed during the 
calendar year 1998 to 2012
2169 included for the association analysis (Figure 4A-
D) with treatment-failing patients
(A) Recently-infected, treatment-na¨ıve pop-
ulation
449198 viral loads measured before 1.1.2013 from 
17835 patients enrolled in the SHCS
307479 viral loads < 400 copies/ml
34152 not measured after 180 days of a 
continuous therapy
38276 viral loads from 5709 treatment-failing patients
1822 viral loads not measured during the 
calendar year 1997 to 2011
36454 viral loads (18097 yearly unique values) from 
5399 treatment-failing patients in the years 1997-2011 
included for the association analysis (Figure 4E)
5327 viral loads from 2932 treatment-failing patients 
with corresponding GRTs
31127 viral loads not having a 
corresponding GRT
379907 viral loads from 14274 treatment-experienced 
patients
69291 viral loads measured before 
patients started therapy
The number of viral loads (yearly unique values) from 
the number of patients carrying the specific mutation 
used for association analysis (Figure 4F,G,H):
M184V: 2384 (2159) from 1513 patients
L90M : 1043 (925) from 497 patients
K103N: 770 (680) from 453 patients
(B) Treatment-failing population
Figure 8.2: Selection profile for the recently-infected, treatment-na¨ıve and the treatment-
failing population
Numbers outside of the box indicate exclusions. (A) Selection profile for the recently-infected, treatment-
na¨ıve population. We selected patients enrolled in the SHCS before Jan.1, 2013 with GRTs performed
when they were treatment-na¨ıve (n=7920). From them we identified patients having GRTs performed
during recent infection (≤ 1 year of infection) according to documented infection dates, seroconversions, or
ambiguity score and CD4 count. These patients thus constitute our basic study population (n=2421). For
further analyses such as for the uni- and multivariable analysis in Table 8.1 and for the association analyses
in Figure 8.4 A-D, 66 and 252 patients were excluded due to additional criteria set for these analyses. 66
patients did not have a clearly defined subtype, and 252 patients were not sampled between 1998 - 2012
(for details see individual descriptions in Table 8.1 and Figure 8.4).
(B) Selection profile for the treatment-failing population. We chose PVL as an indicator for the viral burden
from treatment-failing patients on a population level. PVL was defined as the sum of log10 transformed VLs
from treatment-failing patients. We thus selected available VL measurements from SHCS patients when
they were treatment-experienced. High VLs (≥ 400 copies/m`) measured after 180 days of and during a
continuous therapy were included from these patients. Because VL has been fully integrated into clinical
routine since 1997, values before 1997 were excluded. We calculated a yearly-unique VL from each patient
(if ≥ 1 VL was available per patient within the same year, the mean was used) and used these values for
association analysis in Figure 8.4 E. For further association analyses as in Figure 8.4 F-H, where we studied
the transmission pattern of a specific TDR, only VLs corresponding with a GRT were included because
genotyping was needed to determine drug-resistance mutations. From VLs having corresponding GRTs we
selected those from patients carrying M184V, L90M, or K103N for association analysis in Figure 8.4 F, G,
or H, respectively.
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No. with resistance /  
Total No. in 
subgroup (%)a,b 
OR (95% CI) 
in univariable 
analysis 
p-
value 
OR (95% CI) 
in multivariable 
analysis 
p-
value 
Age 35 (28, 42)c 1.00 (0.98 - 1.01) 0.62   
Ethnicity   0.33   
  Caucasian 182/1985 (9.2) 1.00 (Ref.)    
  Black 16/222 (7.2) 0.77 (0.45 - 1.31)    
  Othersc 9/148 (6.1) 0.64 (0.32 - 1.28)    
HIV Subtype   <0.01  0.03 
  B 167/1683 (9.9) 1.00 (Ref.)  1.00 (Ref.)  
  Non-B 40/672 (6.0) 0.57 (0.40 - 0.82)  0.65 (0.43 - 0.98)  
Sex   0.07  0.10 
  Male 173/1853 (9.3) 1.00 (Ref.)  1.00 (Ref.)  
  Female 34/502 (6.8) 0.71 (0.48 - 1.03)  0.96 (0.60 - 1.55)  
Transmission Groupd   0.03  0.62 
  MSM 129/1248 (10.3) 1.00 (Ref.)  1.00 (Ref.)  
  HSX 52/770 (6.8) 0.63 (0.45 - 0.88)  0.83 (0.52 - 1.30)  
  IDU 22/263 (8.4) 0.79 (0.49 - 1.27)  0.86 (0.51 - 1.45)  
  Others 4/74 (5.4) 0.50 (0.18 - 1.38)  0.57 (0.20 - 1.60)  
No. of available drug classese   0.77  0.06f 
  1 (NRTI) 10/125 (8.0) 0.97 (0.49 - 1.91)  2.99 (0.99 - 9.02)  
  2 (NRTI,PI) 20/220 (9.1) 1.12 (0.68 - 1.84)  2.85 (1.19 - 6.83)  
  3 (NRTI,PI,NNRTI) 25/235 (10.6) 1.33 (0.84 - 2.11)  2.75 (1.36 - 5.55)  
  4 (NRTI,PI,NNRTI,PI/r) 103/1252 (8.2) 1.00 (Ref.)  1.00 (Ref.)  
  5 (NRTI,PI,NNRTI,PI/r,InSTI) 49/523 (9.4) 1.15 (0.81 - 1.65)  0.61 (0.34 - 1.07)  
Year 2005 (2001, 2008)b 1.02 (0.98 – 1.05) 0.32 1.13 (1.03 – 1.23)g 0.01 
a. Number of patients with any drug resistance from the recently-infected, treatment-naïve patients with a 
clearly defined subtype (n = 2355). 
b. For age and year, median (IQR) was shown 
c. Others includes Asian, Hispanic, others, and unknown 
d. MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and 
unknown 
e. NRTI: nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleotide reverse 
transcriptase inhibitor; PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
f. p-value was obtained from the test for trend.  
g. increment is per year 
 
Table 8.1: Univariable and multivariable analysis for the overall TDR prevalences
We used logistic regression to model the odds of being detected as carrying TDR. The dependent variable
was included as a binary response indicating whether any TDR was detected. All co-variables were
categorical except for age and year that were continuous variables. In the multivariable model, we included
significant variables from a univariable model: HIV subtype and transmission group. Variables chosen a
priori to be included regardless of univariable significance were sex, number of available drug classes, and
calendar year. Missing data were list-wise deleted, resulting that 66/2421 = 2.7% of patients were deleted
due to missing subtype.
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Figure 8.3: Observed and predicted TDR prevalences
2421 recently-infected, treatment-na¨ıve patients with their first GRTs were included. For each year we
calculated the percentage of GRTs detecting TDR (black dots) to (A) any drug, (B) NRTI, (C) PI, and (D)
NNRTI. Additionally, we predicted TDR prevalence (blue dashed lines) by holding all co-variables except
for year and number of available drug classes at baseline from the multivariable logistic regression model
(Table 8.1) and transforming the odds obtained from the model. Co-variables included in the model were
HIV-1 subtype and transmission group due to univariable significance and sex, number of available drug
classes, and calendar year that were chosen a priori. Missing data were list-wise deleted. Total numbers of
GRTs included for each year were listed at the bottom (for observed data in black; for predicted data in
blue). The reason for a smaller sample size (n = 2355) for the predicted prevalences was that 66 patients
were excluded from the multivariable model due to non-classified HIV-1 subtypes.
We found that the large fluctuations of the observed TDR prevalences (black dots) could be explained by
two opposing developments: (1) a continuous increase with time when no new drug classes were introduced,
and (2) a sharp decrease when a new drug class was introduced (orange vertical lines). This combined
effect was described by the predicted TDR prevalence (blue dashed lines).
Vertical bars = 95% CI
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Transmitted M184V increased 1.5 fold for an increase of PVL from ART-failing patients
carrying M184V from the previous year by 100 (RR = 1.50/100 PVL [1.20, 1.86]; p <
0.001; Figure 8.4 B,F). This association increased to 6 fold when only TDRs from Swiss
transmission clusters were considered (RR = 5.68/100 PVL [1.21, 26.7]; p = 0.028). On
the contrary, we observed a negative association between the transmitted L90M and PVL
from ART-failing patients carrying L90M from the previous year (RR = 0.75/100 PVL
[0.58,0.96]; p = 0.022; Figure 8.4 C,G); the association became stronger when TDRs
from Swiss transmission clusters were considered (RR=0.07/100 PVL [0.01, 0.46]; p =
0.006). For K103N no association was detected (RR = 1.00/100 PVL [0.73,1.37]; p =
0.99; Figure 8.4 D,H) and RR became negative when including only patients from Swiss
transmission clusters but without reaching significance (RR = 0.02/100 PVL [0.0002, 1.55];
p = 0.078).
Sensitivity analyses using PVL from different years, and validating the ambiguity score
for identifying recent infections showed that our results were robust (Supplementary Table
S2, S3.1, S3.2). For a summary of sample size and method used in each analysis see
Supplementary Table 4.
8.4 Discussion
In this study we investigated the paradox between the decrease in ADR prevalence [132,
230, 252] and a nearly stable prevalence of TDR [231, 233, 234, 248, 253]. If TDR indeed
primarily originate from ART-failing patients with ADR, this discrepancy is counterintu-
itive. We therefore tested whether transmission of drug-resistant viruses was dependent on
ART-failing patients in the SHCS, which is representative for Switzerland, over a 15-year
time period. A large, clearly defined recently-infected, treatment-na¨ıve population was
used to calculate TDR prevalences.
Our results indicate that drug-resistance transmission is not predominantly driven by
treatment-failing patients, but rather by a complex mixture of both ART-failing and ART-
na¨ıve patients. Despite PVL of treatment-failing patients decreased continuously, TDR
prevalences increased over time. When specific TDRs were studied individually, distinct
transmission patterns emerged. The prevalence of transmitted M184V correlated posi-
tively with PVL from ART-failing patients carrying M184V from the previous year. This
association became stronger for patients included in Swiss transmission clusters. This sug-
gests that the treatment-failing population is the major transmission source for M184V.
In contrast, no positive association was found for L90M or K103N. We detected a negative
association between prevalences of transmitted L90M and PVL from ART-failing patients
carrying L90M from the previous year. This implies that major transmission reservoirs
for these mutations are treatment-na¨ıve rather than treatment-failing patients.
How can we explain such divergent transmission patterns between specific drug-resistance
mutations? It is most likely due to the differential fitness costs, which represent the re-
duced ability of a virus harboring a drug-resistance mutation to replicate in the absence of
the drug to which the mutation confers resistance. Generally, drug-resistant viruses will
be replaced gradually by fitter viruses when drug pressure is not present, and the rate of
the replacement depends on the degree of the fitness cost [146]. M184V disappears at a
fast rate after transmission [214] without drug pressure due to its high fitness cost [254].
Therefore, M184V was rarely found in a drug-na¨ıve population and its transmission de-
pends on treatment-failing patients. In contrast, low-fitness-cost mutations L90M and
K103N [178, 213, 255] persist longer in the absence of drug pressure [213], and may there-
fore persist within the ART-na¨ıve population, which thus becomes an important source
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Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
TDR, n=2169 -- 104 120 129 110 136 131 160 194 193 176 186 185 146 122 77
PVL(all failing patients), n=18097 1421 1528 1580 1437 1619 1631 1592 1411 1250 1149 986 813 668 570 442 --
PVL (failing patients with M184V), n=2159 292 253 236 179 233 185 195 176 100 94 74 52 38 30 22 --
PVL (failing patients with L90M), n=925 50 107 111 99 110 90 101 84 54 38 40 19 12 5 5 --
PVL (failing patients with K103N), n=680 6 15 33 51 82 77 103 76 49 47 48 28 32 18 15 --
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Figure 8.4: Association analysis for TDR prevalences with PVL from ART-failing patients
from the previous year
Poisson regression was used to test the association between TDR and PVL from ART-failing patients
from the previous year. 2169 patients with recently-infected, treatment-na¨ıve GRTs during years 1998-
2012 were included as the outcome to account for annual prevalences of (A) any TDR, (B) transmitted
M184V, (C) transmitted L90M, and (D) transmitted K103N. Included as an explanatory variable was (E)
PVL of all ART-failing patients, PVL of ART-failing patients carrying (F) M184V, (G) L90M, and (H)
K103N, respectively, during years 1997 - 2011. Total numbers of GRTs performed from recently-infected,
treatment-na¨ıve patients for each year were listed in the first row of the table at the bottom. Annual
numbers of yearly-unique VLs for all failing patients, noted as PVL (all failing patients), and PVL (failing
patients with a specific mutation) were listed in the second to forth row.
We found that PVL of all treatment-failing patients has decreased over time (E; linear regression: -318
per year [-438, -197]; p < 0.001). Annual prevalences for any TDR was negatively associated with PVL of
treatment-failing patients from the previous year (A, E; RR = 0.91 for every 1000 PVL-all increment [0.83,
0.99]; p = 0.033). Prevalence of transmitted M184V was positively associated with PVL from ART-failing
patients carrying M184V from the previous year (B, F; RR = 1.50 for every 100 PVL increment [1.20,
1.86]; p < 0.001). On the other hand, a negative association and no association was found for L90M (C,
G; RR = 0.75 for per 100 PVL increment [0.58, 0.96]; p = 0.022) and K103N (D, H; RR = 1.00 for per
100 PVL increment [0.73, 1.37]; p = 0.99), respectively.
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for transmission of these mutations.
This interpretation is further supported by the fact that occurrence of L90M among
recently-infected, treatment-na¨ıve patients has increased years after the PVL from ART-
failing patients carrying L90M started to decrease (Figure 8.4), resulting in the negative
association from the Poisson regression. A similar but weaker phenomenon was observed
for K103N. Various combinatorial ART-regimens might contribute to differences between
transmission patterns of L90M and K103N. Drugs selecting for L90M, mainly saquinavir
and nelfinavir, have been almost unused in Switzerland for many years, indicating circu-
lation of transmitted L90M within the treatment-na¨ıve population. On the other hand,
drugs selecting for K103N, such as efavirenz and nevirapine, are still in heavy use, imply-
ing that transmission of K103N is fueled both by treatment-failing and treatment-na¨ıve
patients.
Complemented by results from previous phylogenetic analyses [51, 256, 257], our study
further illustrates that the treatment-na¨ıve population is a major source for ongoing trans-
mission of low-fitness-cost mutations. Early diagnosis and treatment of HIV-1-infected
individuals is warranted to block the otherwise self-fueling mechanism of unrecognized
TDR, which persist in this population due to low fitness costs.
In the SHCS TDR prevalences fluctuated considerably over time. We hypothesized that
introductions of new drugs had an effect on these fluctuations, because new drugs im-
prove control of viremia in treated patients. Indeed, after each introduction of a new drug
class, a drop in TDR prevalences was observed: in 1997 after introduction of PI, 1999
after NNRTI, 2001 after PI/r, and 2009 after InSTI (Figure 8.3). Despite the universal
and unlimited access to ART in Switzerland, TDR prevalences could not be reduced over
an 18-year study period (Figure 8.3 A). Possibly, even more TDRs would have occurred
without a constant influx of new therapy options. This highlights the importance of a
drug pipeline that constantly delivers new medications.
There are several limitations to this study. Although our study was limited to a single
country, we believe that our findings are generalizable to settings with similar HIV epi-
demics and treatment policies (for generalizability see Supplementary Material). In the
correlation analyses we used measures of treatment-failing patients from the previous year
because we assumed that treatment-failing patients could transmit drug-resistance ap-
proximately within one year before salvage treatment is fully active. Sensitivity analyses
using PVL from the same year or two years before revealed similar results to the origi-
nal model (Supplementary Table S2). Furthermore, the lack of positive associations from
individual-mutation analyses of L90M/K103N does not causally prove that treatment-
na¨ıve individuals are the main source for the transmission. Though unlikely due to the
well-studied transmission dynamics within the SHCS [251], we cannot exclude that pa-
tients carrying the transmitted L90M/K103N in our study population might all have been
infected abroad and thus the ART-failing PVL as measured in the SHCS would not be
relevant. However, the subgroup analysis including only patients from Swiss transmission
clusters confirmed the same finding.
Conclusions
We demonstrated that transmission of antiretroviral drug-resistance is temporarily re-
duced by the introduction of new drug classes and driven both by treatment-failing and
treatment-na¨ıve patients. These findings suggest a continuous need for new drugs, early
detection and early treatment of HIV-1 infection to successfully control the spread of TDR
in the long term.
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8.5 Supplementary Materials
1. Generalizability of our findings
2. Supplementary Table S1.1: Multivariable analysis for TDR prevalences against NRTI
3. Supplementary Table S1.2: Multivariable analysis for TDR prevalences against PI
4. Supplementary Table S1.3: Multivariable analysis for TDR prevalences against
NNRTI
5. Supplementary Table S2: Sensitivity analyses for the Poisson regression models in-
cluding PVL from the same year or from previous two years as the independent
variable
6. Supplementary Table S3.1: Sensitivity analysis for the multivariable logistic re-
gression model including additionally the identification by ambiguity score as a
co-variable
7. Supplementary Table S3.2: Sensitivity analyses for the Poisson regression models
including additionally the identification by ambiguity score as a co- variable
8. Supplementary Table 4: Summary of sample size and statistical method
9. Supplementary Figure S1: Representativeness of recently-infected, treatment- naive
patients included in our study according to the estimated numbers of newly diag-
nosed patients from the Swiss Federal Office of Public Health (FOPH) from 1996 -
2012
1. Generalizability: 
The analysis provided in our manuscript originates from Swiss data. The Swiss HIV epidemic resembles very much the 
epidemic in other resource-rich countries in Europe, North America and Australia. These regions have obtained access 
to the same drugs at approximately the same time periods since the first drug AZT was approved in 1987 (sometimes 
there was a delay of 0.5-1 year for some drugs in some countries). Also transmission groups are comparable: MSM and 
heterosexuals and IDUs are the major transmission groups. For this reason, one would expect that the epidemic of 
transmitted drug resistance in these regions follows similar mechanisms as in Switzerland. Of course health systems can 
differ, access to HIV care can vary considerably between countries, which may lead to potentially different treatment 
outcomes and different rates of resistance. The Swiss HIV epidemic is characterized by several aspects: (i) the Swiss 
Health System has a very high standard, (ii) everybody since the beginning of the epidemic had full access to care and 
to all approved drugs independent of social status (this is also valid for immigrants, even asylum seekers during the 
often very lengthy admission procedure), (iii) the SHCS is running since 1988 and has enrolled more than 19’000 
people as per today. A roughly similar cohort study (based on the population of these countries) means that in the US a 
cohort study would need to exist of approx. 830000 people, in Germany of 190’000 and in the UK of 142’500 including 
biobanks to be comparable to the SHCS. (iv) the SHCS has an unbiased approach meaning that all HIV-1 infected 
people of different transmission groups are enrolled at the same treatment centers and therefore obtain the same 
treatment (MSM, HSX, IDU, men, women) by the same ID/HIV-specialists. Taken together, the quality of HIV-1 care 
is good to very good in Switzerland and due to access of care for all HIV-1 infected people the “selection pressure” of 
antiretroviral drugs on the population level is strong. Hence, we believe that findings of our study should be 
generalizable to other developed countries where data needed to perform such an analysis are not available in the same 
manner. Moreover, our findings provide a best-case scenario for settings with a similarly intensive drug use but poorer 
surveillance; especially the finding that curbing the spread of resistance requires even in Switzerland the continuous 
introduction of new drug classes is extremely relevant in this regard: Given scale-ups of ART in many resource limited 
settings with limited means of surveillance, the selection pressure for drug resistance may very soon reach similar 
dimensions as in Switzerland but the same means to counteract it is lacking. Thus the finding that drug resistance 
remains a problem requiring constant introductions of new drug classes despite the nearly optimal conditions of medical 
care and therapy monitoring in Switzerland provides an important warning of the long-term risks associated with HIV 
drug resistance in resource limited settings. 
  
 
  
 
 
 
No. with 
resistance /  
Total No. in 
subgroup (%)b  
OR (95% CI) 
in univariable 
analysis 
P-
value 
OR (95% CI) 
in multivariable 
analysis 
P-
value 
Age 35 (28, 42)b 1.00 (0.98 - 1.01) 0.63   
Ethnicity   0.35   
  Caucasian 117/1985 (5.9) 1.00 (Ref.)    
  Black 11/222 (5.0) 0.83 (0.44 - 1.57)    
  Othersc 5/148 (3.4) 0.56 (0.22 - 1.39)    
HIV Subtype   <0.01  <0.01 
  B 115/1683 (6.8) 1.00 (Ref.)  1.00 (Ref.)  
  Non-B 18/672 (2.7) 0.38 (0.23 - 0.62)  0.38 (0.22 - 0.67)  
Sex      
  Male 108/1853 (5.8) 1.00 (Ref.) 0.46 1.00 (Ref.) <0.01 
  Female 25/502 (5.0) 0.85 (0.54 - 1.32)  1.17 (0.66 - 2.06)  
Transmission Groupd      
  MSM 80/1248 (6.4) 1.00 (Ref.) 0.25 1.00 (Ref.) 0.85 
  HSX 34/770 (4.4) 0.67 (0.45 - 1.02)  0.89 (0.51 - 1.55)  
  IDU 16/263 (6.1) 0.95 (0.54 - 1.65)  0.82 (0.44 - 1.53)  
  Others 3/74 (4.1) 0.62 (0.19 - 2.00)  0.66 (0.20 - 2.21)  
No. of available drug 
classese   0.12  0.31
f 
  1 (NRTI) 9/125 (7.2) 1.54 (0.75 - 3.19)   2.38 (0.65 - 8.69)  
  2 (NRTI,PI) 17/220 (7.7) 1.66 (0.95 - 2.91)  2.44 (0.87 - 6.89)  
  3 (NRTI,PI,NNRTI) 20/235 (8.5) 1.85 (1.09 - 3.13)  2.60 (1.13 - 5.98)  
  4 (NRTI,PI,NNRTI,PI/r) 60/1252 (4.8) 1.00 (Ref.)  1.00 (Ref.)  
  5 (NRTI,PI,NNRTI,PI/r,InSTI) 27/523 (5.2) 1.08 (0.68 - 1.72)  0.80 (0.38 - 1.67)  
Year 2005 (2001, 2008)b 0.97 (0.93 - 1.01) 0.12 1.05 (0.94 - 1.18)
g 0.36 
a.n=2355. Included in the logistic regression as the dependent variable was the binary response indicating whether TDR to NRTI 
was detected. All co-variables were categorical except for age and year which were continuous variables. For consistency we 
included in the multivariable model the same co-variables as in the model for TDR overall in Table 1: HIV subtype, transmission 
group, sex, number of available drug classes, and calendar year. 
b.For age and year, median (IQR) was shown 
c.others includes Asian, Hispanic, others, and unknown 
d.MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and unknown 
e.NRTI: nucleotide reverse transcriptase inhibitor; PI:protease inhibitor; NNRTI: non-nucleotide reverse transcriptase inhibitor; 
PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
f.p-value was obtained from the test for trend. 
g.increment is per year 
Table S1.1: Multivariable analysis for TDR prevalences against NRTIa 
  
 
 
 
 
 
No. with 
resistance /  
Total No. in 
subgroup (%)b  
OR (95% CI) 
in univariable 
analysis 
P-
value 
OR (95% CI) 
in multivariable 
analysisc 
P-
value 
Age 35 (28, 42)b 1.00 (0.98 - 1.02) 0.96   
Ethnicity   0.02   
  Caucasian 59/1985 (3.0) 1.00 (Ref.)    
  Black 2/222 (1.0) 0.30 (0.07 - 1.22)    
  Othersd 1/148 (0.7) 0.22 (0.03 - 1.61)    
HIV Subtype   0.28  0.54 
  B 48/1683 (2.9) 1.00 (Ref.)  1.00 (Ref.)  
  Non-B 14/672 (2.1) 0.72 (0.40 - 1.32)  1.25 (0.62 - 2.54)  
Sex   0.01  0.69 
  Male 56/1853 (3.0) 1.00 (Ref.)  1.00 (Ref.)  
  Female 6/502 (1.2) 0.39 (0.17 - 0.91)  0.72 (0.25 - 2.07)  
Transmission Groupe   <0.01  0.02 
  MSM 47/1248 (3.8) 1.00 (Ref.)  1.00 (Ref.)  
  HSX 12/770 (1.6) 0.40 (0.21 - 0.77)  0.40 (0.16 - 0.98)  
  IDU 3/263 (1.1) 0.29 (0.09 - 0.95)  0.30 (0.08 - 0.96)  
  Others 0/74 (0) -  -  
No. of available drug 
classesf   0.84  0.41
g 
  1 (NRTI) 2/125 (1.6) 0.62 (0.15 - 2.62)  2.01 (0.24 - 16.69)  
  2 (NRTI,PI) 7/220 (3.2) 1.25 (0.55 - 2.88)  3.12 (0.68 - 14.24)  
  3 (NRTI,PI,NNRTI) 8/235 (3.4) 1.34 (0.61 - 2.95)  2.96 (0.86 - 10.15)  
  4 (NRTI,PI,NNRTI,PI/r) 32/1252 (2.6) 1.00 (Ref.)  1.00 (Ref.)  
  5 
(NRTI,PI,NNRTI,PI/r,InSTI) 13/523 (2.5) 0.97 (0.51 - 1.87)  0.53 (0.19 - 1.44)  
Year 2005 (2001, 2008)b 1.01 (0.96 - 1.07) 0.75 1.09 (0.93 - 1.29)h 0.26 
Table S1.2: Multivariable analysis for TDR prevalences against PIa 
a. n=2355. Included in the logistic regression as the dependent variable was the binary response indicating whether TDR 
to PI was detected. All co-variables were categorical except for age and year which were continuous variables. For 
consistency we included in the multivariable model the same co-variables as in the model for TDR overall in Table 1: 
HIV subtype, transmission group, sex, number of available drug classes, and calendar year. 
b. For age and year, median (IQR) was shown 
c. 74 patients were omitted from the multivariable model for TDR prevalence to PI as the subgroup “others” of 
transmission group had zero TDR event. n=2281 
d. Others includes Asian, Hispanic, others, and unknown 
e. MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and unknown 
f. NRTI: nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleotide reverse transcriptase 
inhibitor; PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
g. p-value was obtained from the test for trend. 
h. increment per year 
  
 
 
 
 No. with 
resistance /  
Total No. in 
subgroup (%)b  
OR (95% CI) 
in univariable 
analysis 
P-
value 
OR (95% CI) 
in multivariable 
analysisc 
P-
value 
Age 35 (28, 42)b 1.00 (0.98 - 1.03) 0.87   
Ethnicity   0.58   
  Caucasian 40/1985 (2.0) 1.00 (Ref.)    
  Black 5/222 (2.3) 1.12 (0.44 - 2.87)    
  Othersd 5/148 (3.4) 1.70 (0.66 - 4.37)    
HIV Subtype   0.58  0.79 
  B 34/1683 (2.0) 1.00 (Ref.)  1.00 (Ref.)  
  Non-B 16/672 (2.4) 1.18 (0.65 - 2.16)  1.10 (0.54 - 2.25)  
Sex   0.08  0.18 
  Male 44/1853 (2.4) 1.00 (Ref.)  1.00 (Ref.)  
  Female 6/502 (1.2) 0.50 (0.21 - 1.17)  0.42 (0.16 - 1.10)  
Transmission Groupe   0.83  0.58 
  MSM 28/1248 (2.2) 1.00 (Ref.)  1.00 (Ref.)  
  HSX 17/770 (2.2) 0.98 (0.53 -1.81)  1.76 (0.80 - 3.87)  
  IDU 4/263 (1.5) 0.67 (0.23 - 1.93)  1.46 (0.48 - 4.46)  
  Others 1/74 (1.4) 0.60 (0.08 - 4.45)  0.91 (0.12 - 6.98)  
No. of available drug 
classesf   0.11  0.24
g 
  1 (NRTI) 0/125 (0) -  -  
  2 (NRTI,PI) 2/220 (0.9) 0.35 (0.08 - 1.47)  2.54 (0.34 - 19.15)  
  3 (NRTI,PI,NNRTI) 2/235 (0.9) 0.33 (0.08 - 1.37)  1.32 (0.22 - 7.92)  
  4 (NRTI,PI,NNRTI,PI/r) 32/1252 (2.6) 1.00 (Ref.)  1.00 (Ref.)  
  5 (NRTI,PI,NNRTI,PI/r,InSTI) 14/523 (2.7) 1.05 (0.55 - 1.98)  0.32 (0.12 - 0.87)  
Year 2005 (2001, 2008)b 1.13 (1.05 - 1.21) <0.01 1.28 (1.08 - 1.52)h <0.01 
a. n=2355. Included in the logistic regression as the dependent variable was the binary response indicating whether TDR to 
NNRTI was detected. All co-variables were categorical except for age and year which were continuous variables. For 
consistency we included in the multivariable model the same co-variables as in the model for TDR overall in Table 1: HIV 
subtype, transmission group, sex, number of available drug classes, and calendar year. 
b. For age and year, median (IQR) was shown 
c. 125 patients were omitted from the multivariable model for TDR prevalence to NNRTI as the subgroup 5 of number of 
available drug classes had zero TDR event. n=2230 
d. Others includes Asian, Hispanic, others, and unknown 
e. MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and unknown 
f. NRTI: nucleotide reverse transcriptase inhibitor; PI:protease inhibitor; NNRTI: non-nucleotide reverse transcriptase inhibitor; 
PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
g. p-value was obtained from the test for trend. 
h. increment is per year 
Table S1.3: Multivariable analysis for TDR prevalences against NNRTIa 
  
 
dependent and 
independent 
variables included in 
the model 
PVL from the 
previous year 
(original model) 
 
PVL from the 
same year 
(sensitivity 
analysis) 
 
PVL from two 
years before 
(sensitivity 
analysis) 
 
 OR (95% CI) p-value OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
TDR prevalence with 
PVL of ART-failing 
patients 
0.91 (0.83 - 0.99)  0.03 0.92 (0.85 - 0.99) 0.03 0.91 (0.82 -1.01) 0.09 
Prevalence of 
transmitted M184V 
with PVL of ART-
failing patients 
carrying M184V 
1.50 (1.20 - 1.86) <0.01 1.36 (1.15 - 1.61) <0.01 1.60 (1.21 - 2.10) <0.01 
Prevalence of 
transmitted L90M 
with PVL of ART-
failing patients 
carrying L90M 
0.75 (0.58 - 0.96) 0.02 0.74 (0.58 - 0.96) 0.02 0.76 (0.59 -0.98) 0.04 
Prevalence of 
transmitted K103N 
with PVL of ART-
failing patients 
carrying K103N 
1.00 (0.73 - 1.37) 0.99 0.93 (0.67 - 1.29) 0.67 1.21 (0.89 - 1.64) 0.24 
Patients found in 
Swiss transmission 
clusters 
      
TDR prevalence with 
PVL of ART-failing 
patients 
0.76 (0.43 - 1.33) 0.34 0.86 (0.52 - 1.43) 0.56 0.70 (0.38 - 1.33) 0.28 
Prevalence of 
transmitted M184V 
with PVL of ART-
failing patients 
carrying M184V 
5.68 (1.21 - 26.7) 0.03 2.38 (0.79 -7.13) 0.12 13.6 (0.73 -254.5) 0.09 
Prevalence of 
transmitted L90M 
with PVL of ART-
failing patients 
carrying L90M 
0.07 (0.01 -0.46) <0.01 0.04 (0.004 - 0.35) <0.01 0.07 (0.01 - 0.47) <0.01 
Prevalence of 
transmitted K103N 
with PVL of ART-
failing patients 
carrying K103N 
0.02 (0.0002-1.55) 0.08 0.30 (0.01 - 7.10) 0.46 0.86 (0.07 - 10.4) 0.90 
a.As sensitivity analyses we replaced the dependent variable, PVL from the previous year, with PVL from the same year with 
GRT, and from two years before GRT. Same analyses were repeated for patients found in Swiss transmission clusters.  
Table S2: Sensitivity analyses for the Poisson regression models including PVL 
from the same year or from previous two years as the independent variablea 
  
 
 Original model  Sensitivity analysis  
Variablesb OR (95% CI) 
in multivariable analysis p-value 
OR (95% CI) 
in multivariable analysis p-value 
HIV Subtype  0.03  0.03 
   B 1.00 (Ref.)  1.00 (Ref.)  
   NonB 0.65 (0.43 - 0.98)  0.64 (0.43 - 0.97)  
Sex  0.10  0.10 
   Male 1.00 (Ref.)  1.00 (Ref.)  
   Female 0.96 (0.60 - 1.55)  0.95 (0.59 - 1.52)  
Transmission Groupc  0.62  0.62 
   MSM 1.00 (Ref.)  1.00 (Ref.)  
   HSX 0.83 (0.52 - 1.30)  0.81 (0.51 - 1.28)  
   IDU 0.86 (0.51 - 1.45)  0.87 (0.51 - 1.46)  
   Others 0.57 (0.20 - 1.60)  0.57 (0.20 - 1.62)  
No. of available drug 
classesd 
 0.06e  0.07e 
   1 (NRTI) 2.99 (0.99 - 9.02)  3.00 (0.98 -9.15)  
   2 (NRTI, PI) 2.85 (1.19 - 6.83)  3.04 (1.26 - 7.33)  
   3 (NRTI,PI,NNRTI) 2.75 (1.36 - 5.55)  2.84 (1.40 - 5.79)  
   4 (NRTI,PI,NNRTI,PI/r) 1.00 (Ref.)  1.00 (Ref.)  
   5 (NRTI,PI,NNRTI,PI/r,InI) 0.61 (0.34 - 1.07)  0.66 (0.37 - 1.17)  
Year  1.13 (1.03 - 1.23) 0.01 1.13 (1.03 - 1.24) 0.01 
Identification by ambiguity   1.22 (0.91 - 1.64)f 0.20 
 
 
 
a.This is to test the validity of ambiguity score to identify recent infections. We included additionally a binary co-variable in the 
multivariable logistic regression model showing whether a patient was identified as being recently-infected by ambiguity score. 
Results from the sensitivity analysis were shown on the right side. 
b.Only variables included in the multivariable model were listed. 
c.MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and unknown 
d.NRTI: nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleotide reverse transcriptase inhibitor; 
PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
e.p-values were obtained from the test for trend. 
f.Increment is per year 
Table S3.1: Sensitivity analysis for the multivariable logistic regression model 
including additionally the identification by ambiguity score as a co-variablea 
  
 
 Original model  Sensitivity analysis  
 OR (95% CI) p-value OR (95% CI) p-value 
TDR prevalence with PVL 
of ART-failing patients 0.91 (0.83 - 0.99)  0.03 0.87 (0.78 - 0.99) 0.03 
Prevalence of transmitted 
M184V with PVL of ART-
failing patients carrying 
M184V 
1.50 (1.20 - 1.86) <0.01 1.67 (1.18 - 2.37) <0.01 
Prevalence of transmitted 
L90M with PVL of ART-
failing patients carrying 
L90M 
0.75 (0.58 - 0.96) 0.02 0.83 (0.62 - 1.12) 0.23 
Prevalence of transmitted 
K103N with PVL of ART-
failing patients carrying 
K103N 
1.00 (0.73 - 1.37) 0.99 1.03 (0.74 - 1.44) 0.85 
 
 
  
a.This is to test the validity of ambiguity score to identify recent infections. We included additionally a binary co-variable in the 
multivariable logistic regression model showing the fraction of GRTs identified by ambiguity score. Results from the sensitivity 
analysis were shown on the right side. 
 
Table S3.2: Sensitivity analyses for the Poisson regression models including 
additionally the identification by ambiguity score as a co-variablea 
  
 
 
  
Supplementary Table 4: Summary of sample size and statistical method 
 
Analysis Sample size Method 
Fraction of positive 
GRTs in Figure 1 
•10504 GRTs from 7920 treatment-
naïve patients 
•9616 GRTs from 4816 treatment-
experienced patients 
We calculated the annual percentages of 
GRTs detecting any drug-resistance 
mutations from patients of both groups 
Prevalences of TDR 
in Figure 3 
•2421 recently-infected, treatment-
naïve patients with their first GRTs 
We calculated the annual percentages of 
GRTs detecting any drug-resistant, NRTI, 
PI, or NNRTI-resistant mutations 
Uni-/multivariable 
analysis in Table 2 
and prediction of 
TDR prevalences in 
Figure 3 
•2355 recently-infected, treatment-
naïve patients  
Model: logistic regression. Outcome: 
binary response of TDR detection 
Predictive prevalences were transformed 
from odds.  
Association analysis 
for any drug-
resistance 
mutations in Figure 
4A, 4E 
•2169 recently-infected, treatment-
naïve patients (during years 1998-
2012) 
•5327 VLs from 2932 treatment-
failing patients (during years 1997-
2011) 
Model: Poisson regression. Outcome: 
TDR prevalences  
Explanatory: PVL from ART-failing 
patients 
Association analysis 
for M184V in Figure 
4B, 4F 
•2169 recently-infected, treatment-
naïve patients (during years 1998-
2012) 
•2384 VLs (2159 yearly-unique 
VLs) from 1513 ART-failing 
patients 
Model: Poisson regression. Outcome: 
prevalences of transmitted M184V 
Explanatory: PVL from ART-failing 
patients with M184V 
Association analysis 
for L90M in Figure 
4C, 4G 
•2169 recently-infected, treatment-
naïve patients  
•1043 VLs (925 yearly-unique VLs) 
from 497 ART-failing patients 
Model: Poisson regression. Outcome: 
prevalences of transmitted L90M 
Explanatory: PVL from ART-failing 
patients with L90M 
Association analysis 
for K103N in Figure 
4D, 4H 
• 2169 recently-infected, treatment-
naïve patients  
• 770 VLs (680 yearly-unique VLs) 
from 453 ART-failing patients 
Model: Poisson regression. Outcome: 
prevalences of transmitted K103N 
Explanatory: PVL from ART-failing 
patients with K103N 
 
  
Analysis Sample size Method 
 
Association analysis 
for any drug-
resistance mutations 
for people in Swiss 
transmission clusters  
• 632 recently-infected patients 
• 5168 VLs from 1490 ART-failing 
patients 
Model: Poisson regression for patients in 
Swiss transmission clusters 
Outcome: TDR prevalences  
Explanatory: PVL from ART-failing patients  
Association analysis 
for M184V for people 
found in Swiss 
transmission clusters  
• 632 recently-infected patients 
• 598 VLs from 418 ART-failing 
patients 
Model: Poisson regression for patients in 
Swiss transmission clusters 
Outcome: prevalences of transmitted 
M184V 
Explanatory: PVL from ART-failing patients 
with M184V 
Association analysis 
for L90M for people 
found in Swiss 
transmission clusters  
• 632 recently-infected patients 
• 213 VLs from 118  ART-failing 
patients 
Model: Poisson regression for patients in 
Swiss transmission clusters 
Outcome: prevalences of transmitted L90M 
Explanatory: PVL from ART-failing patients 
with L90M 
Association analysis 
for K103N for people 
found in Swiss 
transmission clusters  
• 632 recently-infected patients 
• 148 VLs from 112 ART-failing 
patients 
Model: Poisson regression for patients in 
Swiss transmission clusters 
Outcome: prevalences of transmitted 
K103N 
Explanatory: PVL from ART-failing patients 
with K103N 
 
  
Supplementary Figures 
Figure S1: Representativeness of recently-infected, treatment-naïve patients 
included in our study according to the estimated numbers of newly diagnosed 
patients from the Swiss Federal Office of Public Health (FOPH) from 1996 - 2012  
According to the Swiss Federal Office of Public Health (FOPH), between 500 - 1000 people were estimated to be newly diagnosed each 
year from 1996 to 2012, resulting 11870 cases in total. This was in approximate accordance to the number of participants enrolled into 
the SHCS during the same time period (n=10050 from 1996-2012, dark gray bars and black dots, be aware of the log scale of this 
figure). Thus, for the time primarily studied in our paper, 1996-2012, the coverage of the SHCS is approximately 85% Among the newly 
diagnosed patients, 11% to 28% were included as being recently-infected in our study (blue squares) as defined in the method section. 
From 1996-2012 we included 2386 recently-infected, treatment-naïve patients (35 patients before year 1995 were not used for this 
graph).  
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Abstract
Transmission of drug-resistant pathogens presents an almost-universal challenge for fight-
ing infectious diseases. Transmitted drug resistance mutations (TDRM) can persist in the
absence of drugs for considerable time. It is generally believed that differential TDRM
persistence is caused, at least partially, by variations in TDRM fitness costs. However, in
vivo epidemiological evidence for the impact of fitness costs on TDRM-persistence is rare.
Here, we studied the persistence of TDRM in HIV-1 using longitudinally-sampled nu-
cleotide sequences from the Swiss HIV Cohort Study (SHCS). All treatment-na¨ıve indi-
viduals with TDRM at baseline were included. Persistence of TDRM was quantified via
reversion rates (RR) determined with interval-censored survival models. Fitness costs of
TDRM were estimated in the genetic background in which they occurred using a previ-
ously published and validated machine-learning algorithm (based on in vitro replicative
capacities) and were included in the survival models as explanatory variables.
In 857 sequential samples from 168 treatment-na¨ıve patients, 17 TDRM were analyzed.
RR varied substantially and ranged from 174.0/100 person years; 95% CI, [51.4, 588.8]
(for 184V) to 2.7/100 person years; [0.7, 10.9] (for 215D). RR increased significantly with
fitness cost (increase by 1.6 [1.3, 2.0] per standard deviation of fitness costs). When sub-
dividing fitness costs into the average fitness cost of a given mutation and the deviation
from the average fitness cost of a mutation in a given genetic background, we found that
both components were significantly associated with reversion rates.
Our results show that the substantial variations of TDRM persistence in the absence
of drugs are associated with fitness-cost differences both among mutations and among
different genetic backgrounds for the same mutation.
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Abstract
Transmission of drug-resistant pathogens presents an almost-universal challenge for fight-
ing infectious diseases. Transmitted drug resistance mutations (TDRM) can persist in the
absence of drugs for considerable time. It is generally believed that differential TDRM-per-
sistence is caused, at least partially, by variations in TDRM-fitness-costs. However, in vivo
epidemiological evidence for the impact of fitness costs on TDRM-persistence is rare.
Here, we studied the persistence of TDRM in HIV-1 using longitudinally-sampled nucleo-
tide sequences from the Swiss-HIV-Cohort-Study (SHCS). All treatment-naïve individuals
with TDRM at baseline were included. Persistence of TDRM was quantified via reversion
rates (RR) determined with interval-censored survival models. Fitness costs of TDRM were
estimated in the genetic background in which they occurred using a previously published
and validated machine-learning algorithm (based on in vitro replicative capacities) and were
included in the survival models as explanatory variables.
In 857 sequential samples from 168 treatment-naïve patients, 17 TDRMwere analyzed.
RR varied substantially and ranged from 174.0/100-person-years;CI=[51.4, 588.8] (for 184V)
to 2.7/100-person-years;[0.7, 10.9] (for 215D). RR increased significantly with fitness cost (in-
crease by 1.6[1.3,2.0] per standard deviation of fitness costs). When subdividing fitness costs
into the average fitness cost of a given mutation and the deviation from the average fitness
cost of a mutation in a given genetic background, we found that both components were signifi-
cantly associated with reversion-rates.
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9.1 Introduction
Drug-resistant pathogens represent one of the major public health and clinical challenges
in infectious diseases (http://www.who.int/drugresistance/en/). It is an almost uni-
versal observation that as soon as a chemotherapeutic agent against a given pathogen is
introduced, resistant pathogen strains emerge, which reduce the clinical benefits conferred
by that agent. One crucial obstacle in curbing drug resistance is that once it has emerged
it often persists even in the absence of drug pressure. The central concept here is pathogen
fitness: whereas the resistant pathogen has a very strong advantage over the sensitive one
in the presence of drug pressure, its disadvantages in the absence of treatment are typically
weaker and can be compensated by other mechanisms such as compensatory mutations
or selection at linked loci. Despite this key role of pathogen fitness for a conceptual un-
derstanding of the spread and persistence of drug resistance, real-world epidemiological
examples documenting its role are rare. An ideal opportunity to assess this role of fitness
is provided by the dynamics of antiretroviral resistance in HIV-1.
In the case of HIV, combinations of modern anti-retroviral treatment (ART) have suc-
cessfully reduced the morbidity and mortality of HIV-1 infected individuals [258]. Though
drug resistance prevalence has been shown to decrease or to stabilize in various indus-
trialized countries due to successful ART, it still remains a major concern jeopardizing
treatment success [132, 259].
Transmission of a drug-resistant virus has been observed in most countries where ART
is available [231, 243, 253, 260–263]. After transmission, viruses with transmitted drug
resistance mutations (TDRM) persist either as the dominant species or as minority vari-
ants, which are difficult to detect by population sequencing techniques [213, 214, 220, 224,
244, 264, 265]. Consequently, patients harboring TDRM have a higher chance to fail their
first-line therapy [218, 244, 266, 267].
Several studies have illustrated that the persistence time of individual TDRM in the
absence of drug pressure exhibits substantial variance [178, 213, 214, 224, 265, 268]. Per-
sistence times have been suggested to be associated with fitness costs [266], which are
typically measured as the reduction of replicative capacity of the virus caused by a given
mutation [178]. It is generally assumed that transmitted drug-resistant viruses revert more
rapidly to wild-type viruses if the fitness is reduced to a larger extent by the TDRM
(high fitness cost) because then reversion of TDRM confers correspondingly high fitness
gains [146]. Several studies have measured the fitness of some specific TDRM using phe-
notypic replicative capacity assays [178, 260, 265]. However, evidence for the impact of
such fitness costs on the dynamics of TDRM at an in vivo and epidemiological level is
largely lacking. Here, we aimed to determine the persistence times of TDRM in an epi-
demiological approach in vivo and to determine whether these persistence times depend
on the fitness costs of TDRM.
9.2 Methods
Study population
The SHCS is a prospective, nationwide, clinic-based study including a biobank. The SHCS
is very representative of the HIV epidemiology in Switzerland; it includes at least 53% of
all HIV cases ever diagnosed in Switzerland, 72% of all patients receiving ART, and 69%
of the nationwide registered AIDS cases [10, 242]. Since 1996, the SHCS includes approxi-
mately 85% of the newly diagnosed HIV infected individuals in Switzerland. This number
was obtained when we compared the estimated numbers of newly diagnosed HIV cases
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published by the Swiss Federal Office of Public Health to the numbers of patients enrolled
in the SHCS annually since 1996. Genotypic resistance data stem from routine clinical
testing and from systematic retrospective sequencing before routine genotyping was in-
troduced (over 11000 sequences were retrospectively generated). Genotyping is performed
by four laboratories in Switzerland authorized by the Federal Office of Public Health. All
laboratories perform population-based sequencing of the full protease gene and at least
codons 28 - 225 of the reverse transcriptase gene using commercial assays such as Viroseq
Vs.1 PE Biosystems; Virsoseq Vs. 2, Abbott AG; VircoTYPE HIV-1 Assay, Virco Lab
or in-house methods [243] and has participated in the yearly quality control evaluation
by the Agence Nationale de la Recherche du SIDA(ANRS) since 2002. All sequences are
stored the SHCS drug resistance database using SmartGene’s Integrated Dababase Net-
work System (SmartGene, Zug, Switzerland, IDNS version 3.6.3) [244]. For details on the
sequencing procedure, see [244]. To increase coverage, we have systematically selected all
treatment-na¨ıve individuals carrying TDRM and retrieved their sequential plasma samples
before therapy from the SHCS biobank.
For this study we considered genotypic resistance test (GRT) performed for a patient
when being treatment-na¨ıve. All sequential GRTs were included for individuals hav-
ing ≥ 2 GRTs and harboring TDRM at baseline before ever starting any antiretrovi-
ral therapy. TDRM was defined according to the WHO surveillance list of transmitted
HIV drug resistance [224]. We studied mutations to the major three drug classes: nu-
cleoside and nucleotide analogue reverse transcriptase inhibitors (NRTIs), protease in-
hibitors (PIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Addition-
ally, we excluded 17 potential super-infections based on phylogenetic distance and the
lack of phylogenetic clustering. Finally, since TDRM in HIV-1 CTL epitopes can dis-
rupt binding to the HLA allele and such CTL-escape may essentially influence the re-
version dynamics, we screened the list of optimal HIV-1 CTL epitopes (according to
the Los Alamos HIV database, http://www.hiv.lanl.gov/content/immunology/pdf/
2013/optimal_ctl_article.pdf) for epitopes containing TDRM and excluded from our
analysis those mutations that disrupted binding to the epitope according to NetMHCcons
(http://www.cbs.dtu.dk/services/NetMHCcons/).
Ethics statement
The SHCS, enrolling HIV-infected adults aged ≥ 16 years old, has been approved by
ethics committees of all participating institutions. The data collection was anonymous
and written informed consent was obtained from all participants [242].
Survival analysis
Our goal was to assess systematically the persistence of TDRM in the absence of drug
pressure. In particular we considered the persistence across different mutations and vi-
ral genetic backgrounds (for a given mutation occurring in a given virus, the viral genetic
background is given by the entire amino acid sequence in which this mutation is observed).
To allow inter-patient comparisons we included TDRM that were present in at least five
individuals at baseline.
We quantified the persistence via calculating reversion rates of individual TDRMs. Re-
version of a TDRM was defined as an event at which a TDRM becomes undetectable by
population sequencing assays. In other words, a TDRM has reversed when the HIV vari-
ant carrying that TDRM has decreased to the level below the detection limit of population
sequencing assays (≈ 20 − 30% [269]). Therefore, reversion is not necessarily always to
wild type. We fitted our data with an interval-censored survival model using exponential
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waiting times. We chose an interval-censored model because the data did not allow us to
determine the exact time point of reversion; instead a GRT not detecting a given resis-
tance mutation preceded by a GRT with that mutation informs that the reversion event
must have occurred in the time interval between those two tests.
Our results were expressed with 95% CI and two-sided p-values with p < 005 being sta-
tistically significant. We analyzed our data with Stata 13.1 SE (StataCorp, Texas, USA).
Estimation of fitness costs of TDRM
We estimated fitness costs based on a previously published approach to predict HIV
replicative fitness from amino acid sequences [270]. This approach uses a machine-learning
algorithm (ridge regression) trained on > 70000 data points, each consisting of a pol -
amino-acid sequence and an in vitro replicative capacity. Specifically, the algorithm pre-
dicts replicative capacity (pRC) from an amino acid sequence by a quadratic fitness model
of the form
pRC(x) =
∑
ij
Mijxixj
where xi denotes the presence (1) or absence (0) of a given mutation i and Mij the epistatic
effects (i < j) and the main effects (i = j) characterizing the fitness landscape. These
coefficients were derived in [270] by fitting the model to the > 70000 data points. Since
the number of parameters of the above model exceeds the number of data points, this
model was fitted using an approach based on ridge regression. In essence, in this approach
the data set was split into a training, training-test, and true-test data set. Then assuming
a given penalty weight for model parameters, the model parameters are determined such
that for the training data set, the sum of squared residuals plus the sum of squares of
parameters times the penalty weight are minimized. In this specific case the approach was
modified to a generalized linear ridge regression to take the non-normal error structure into
account. The model was evaluated on the test-training data set, and the penalty weight
was determined such that the predictive power on the test-training test was optimized.
This final model was then evaluated on the true-test data set (which was used neither
in deriving the model parameters nor in determining the penalty weight). Details on the
method and validation on in vitro and clinical data can be found in [270] and [271].
Using this model, we estimated the fitness cost of a mutation in a given genetic background
as follows. If A denotes the partial pol -amino-acid sequence (first 404 amino acid used
in the reference [270]) with a given resistance mutation m and A′ the same amino acid
sequence but with the mutation reverted to its wild-type allele, then the fitness cost of
the mutation m in the background A can be estimated as
c(m,A) = pRC(A)pRC(A′).
A negative fitness cost was set to zero.
The impact of this fitness cost was assessed in univariable and multivariable versions of
the interval-censored model. The multivariable models were adjusted for whether a given
TDRM was present as a mixture with another amino acid at this position. Specifically,
this was considered to be the case if the nucleotide sequence coding for this mutation
contained at least one ambiguous nucleotide that affects the amino acid encoded.
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Patients included 168
Age at baseline 35 (30.5, 40)
Gender
  Male 133 (79.2)
  Female 35 (20.8)
Ethnicity
  White 147 (87.5)
  Black 11 (6.5)
  Others / Unknown 10 (6.0)
Transmission route
  MSM (Male Homosexual) 83 (49.4)
  Heterosexual 47 (28.0)
  Intravenous drug users 33 (19.6)
  Unknown 5 (3.0)
Subtype
  B 137 (81.5)
  Non-B 26 (15.5)
  Non-classified 5 (3.0)
Viral load at baseline (log10 copies/ml) a 4.4 (3.6, 4.9)
CD4 count at baseline (cells/mmc) b 494 (347, 656)
No. of mutations at baseline
  1 101 (60.1)
  2 34 (20.2)
  ≥ 3 33 (19.6)
Mutations at baseline resistant to 
  NRTI 101 (60.1)
  PI 51 (30.4)
  NNRTI 47 (28.0)
No. of resistant classes c at baseline
  1 142 (84.5)
  2 21 (12.5)
  3 5 (3.0)
Test interval in days 193 (170, 243)
Number of GRT performed 7 (4, 11)
a within 30 days before / after the first resistance test, N = 151 (90%)
b within 30 days before /after the first resistance test, N = 157 (93%)
c having ≥ 1 resistant mutations of a drug class
Table 9.1: Basic characteristics of study population
No. of patients (%) or Median (IQR) was shown.
76 CHAPTER 9. RESEARCH PROJECT 2
9.3 Results
Study population
From 7920 treatment-na¨ıve patients enrolled in the SHCS from May 1995 to February
2013, we could identify 987 sequential GRTs from 197 patients, who had ≥ 2 GRT while
being treatment-na¨ıve and presented with ≥ 1 TDRM at baseline. See S1 Table for all
types and numbers of mutations and reversions observed from these 197 patients. The
criterion that a given mutation must have been present in at least 5 individuals at baseline
reduced the number of sequential GRTs and patients to 857 and 168, respectively.
From our studied population most individuals were male (80%), white (87.5%), and in-
fected with subtype-B viruses (81.5%; Table 9.1). The median (IQR) number of GRT
performed per person was 7 (4, 11) and the median (IQR) of test interval was 193 (170,
243) days. Baseline CD4 count was relatively high (494 [347, 656]), suggesting that patients
were tested relatively early on after infection. 60.1% of patients had a single mutation
detected at their first GRT. Detailed patient characteristics were shown in Table 9.1.
Reversion rate of individual TDRM varies
In total, 21 TDRM were analyzed. One mutation (190A of NNRTI) was excluded because
we observed no reversion at all from the studied patients and three mutations (101E,
181C, 210W) were further excluded because they were located in the HLA epitopes (see
Methods). Thus we could obtain reversion rates for 17 TDRM (Fig 9.1). Among them,
10 were mutations associated with resistance to NRTI, 6 to PI, and 1 to NNRTI. The
quantified linear reversion rate showed that persistence time varied strongly among muta-
tions. Among three drug classes, NRTI mutations showed the largest variability. Both the
fastest and the slowest reversion rates, 174.0/100 person years [confidence interval = 51.4,
588.8] from 184V and 2.7/100 person years [0.7, 10.9] from 215D, respectively, belonged
to this drug class.
Predicted fitness cost is associated with TDRM persistence
We found that reversion rates were associated significantly with the predicted fitness costs
of resistance mutations (Fig 9.2). Specifically, the survival analysis with predicted fitness
cost as an explanatory variable yielded that reversion rates increased by a factor 1.6 [1.3,
2.0] (p < 0.001) if fitness is increased by one standard deviation. Thus, predicted fitness
has a considerable and highly significant impact on reversion rates. Since this analysis
included different fitness costs of mutations, each in at least five patients, the observed
effect of fitness can be caused by two mechanisms: On the one hand, by overall differences
in costs among mutations (main effects) and, on the other hand, by different costs of the
same mutation in different backgrounds (epistatic effects). In order to distinguish between
these two effects, we further analyzed the data with two alternative approaches:
In the first approach, we still used predicted fitness cost as the explanatory variable but
adjusted for the identity of the resistance mutation (i.e. the type of resistance mutation
was included as a categorical variable). In this approach, the estimated effect of fitness
corresponded to the impact of fitness within a given type of mutation. Since this approach
introduced 17 variables for 264 data points and 62 events (and hence carries the risk of
over-parameterization), we considered an alternative second approach, which only included
two parameters. Specifically, we divided fitness cost into two components: the mean fitness
cost of a mutation (across backgrounds) and the residual fitness cost, which is given as
the difference between the predicted fitness cost in a given background and the mean
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Figure 9.1: Reversion rate of individual TDRM
Reversion rate was quantified via an interval-censored survival model using an exponential distribution.
The table below showed the number of reversion and total number observed at baseline for each TDRM.
NRTI resistance mutations showed the largest variability that included both the fastest (184V) and the
slowest (215D) reverting TDRM.
fitness cost. In the first approach, reversion rate was increased by a factor 1.8 [1.1, 3.1]
(p < 0.001) if fitness cost was increased by one standard deviation (after adjusting for
type of mutation). In the second approach, both mean fitness cost and residual fitness
cost increased the reversion rate significantly by a factor 1.7 [1.3, 2.1] (p < 0.001) and 1.4
[1.1, 1.8] (p = 0.007) per standard deviation, respectively. Thus our models predict that a
typical difference in fitness cost among resistance mutations (i.e. one standard deviation
of the fitness costs observed in our data set), causes a 40% - 80% increase in the rate with
which resistance mutations revert. Moreover, both approaches showed that both types
of fitness cost (different overall costs of drug resistance mutations, and different costs in
different backgrounds) are associated with higher reversion rates.
These multivariable models also showed that, as can be expected, reversion occurs much
faster if a given TDRM is present as a mixture (see Methods, Table 9.2).
Univar. HR (95% CI ) p Multivar. HR (95% CI ) p
Mean fitness cost 1.31 (1.05,1.64) 0.015 1.65 (1.30,2.10) <0.001
Residual fitness cost 1.34 (1.08,1.66) 0.008 1.38 (1.09,1.75) 0.007
TDRM present as mixture 9.71 (5.87,16.1) <0.001 12.3 (7.22, 20.1) <0.001
Table 9.2: Hazard ratios (HR) reported in univariable and multivariable models
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Figure 9.2: Impact of fitness cost on reversion rates
In unadjusted survival analysis (fitness cost), in survival analysis adjusted for type of mutation (fitness
cost adj.). Impact of mean fitness cost and residual fitness cost in univariable analysis (uvar.) and in
multivariable analysis including both mean and residual fitness cost (mvar.).
9.4 Discussion
In this study we investigated the differential persistence behaviors of TDRM in the absence
of drug pressure and analyzed the association of the reversion rate with the predicted fit-
ness cost of a given mutation. We used an interval-censored survival model to quantify the
reversion rate of each mutation that was at least harbored by five individuals at baseline.
We observed that the reversion rate of individual mutations varied substantially. More-
over, the reversion rates were significantly associated with the differential fitness costs of
the TDRM: We showed that both the fitness-cost differences among mutations and among
viral genetic backgrounds for the same mutation contributed to the variation in reversion
rates. Thus, the novelty of this study is that we compared in total 17 TDRM from patients
in a single cohort and could associate the persistence times with fitness costs of mutations
predicted by a machine-learning model. An additional strength of this study is the high
frequency and the number of resistance tests performed per patient.
Our results were consistent with most studies showing that M184V disappeared
rapidly [178, 214, 215] whereas most thymidine analogue associated mutations (TAMs:
41L, 67N, 70R, 215Y, 219Q) disappeared at a slower rate [178, 215, 272] with the excep-
tion of 70R and 215Y. It is known, however, that 215Y has a high impact on fitness [178]
and is rapidly replaced by intermediate 215S or atypical variants 215C/D [273]. Addition-
ally, the fitness cost of 70R was shown to be higher when combined with other mutations
in vitro [178, 242]. This could explain the observed high reversion rate of 70R regardless
of its low fitness cost because in our data set 7 from 11 patients harboring 70R had at
least one other mutation. Our data showed that most TDRM to PI reverted more rapidly,
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compared to NRTI mutations.
From a more general perspective our findings have important implications for understand-
ing the epidemic spread of drug-resistant pathogens. One of the general problems with
drug resistance is that it can be quickly selected by drug pressure, but upon transmission
it reverts only slowly if at all in the absence of drug pressure [274]. The intuition behind
this is that drugs cause an enormous reduction in the replicative capacity of wild-type
virus and hence lead to a strong relative fitness benefit for resistant mutants. By contrast,
the fitness cost in the absence of drugs is typically weak. Our results highlight the large
variability in reversion rates and the central role of fitness cost in governing the speed
of reversion in the in vivo setting within the SHCS. In particular, they show that the
genetic background of a resistance mutation substantially modulates the fitness cost and
thereby the reversion rate of the mutation. This implies heritable variation in the fitness
cost of resistance and thereby the danger that such fitness costs are reduced by evolu-
tionary selection, i.e. mutations in genetic backgrounds causing lower fitness cost will
have larger chances to spread to other patients and hence may dominate the population
in the long run. Assessing the impact of the genetic background on reversion rates is
central for understanding the spread of antimicrobial resistance in general. For example,
theoretical models and in vitro evidence suggest a crucial role of compensatory mutations
in boosting antibiotic resistance for a broad range of bacterial pathogens [275]. However,
real-world epidemiological evidence for an impact of the genetic backgrounds found in
natural pathogen populations on reversion of resistance in patients is largely lacking. In
this context our approach offers a proof of principle for using machine learning approaches
to bridge the gap between epidemiological data on resistance reversion and in vitro fitness
measurements and thereby to address this crucial issue.
In the context of HIV epidemiology in Switzerland, such a scenario of mutation evo-
lution can be probably prevented by the good surveillance and the early treatment of
HIV-infected individuals, implying that resistant strains have only limited opportunity to
cause new infections and hence to select backgrounds with lower fitness cost. By contrast,
this scenario is a very real danger in settings with poorer surveillance and hence ampler
opportunities for resistant viruses to spread. In those settings evolution might indeed suc-
cessfully act on the variation of fitness costs and lead in the long term to resistant viruses
with a low fitness cost.
Previous work [266] has assessed fitness costs of some antiretroviral resistance mutations
in vitro by site directed mutations (SDM). Since these studies did not consider the im-
pact of different genetic backgrounds, we can only compare the average fitness cost of
a mutation determined by our method with the fitness costs determined by SDM. This
comparison reveals a good qualitative but not perfect agreement to our estimates with
SDM data (as summarized in [266]). Estimates were available in both data sets for the
RT mutations 184V, 70R , 41L, 103N, and 215Y; in agreement with [266] we found a
high fitness cost for 184V (1.8 standard deviations above mean fitness cost = +1.8s.d)
and a moderate fitness cost for 70R , 41L, and 103N ( +0.58 s.d. ,-0.16 s.d., and +0.48
s.d., respectively). In agreement with [266] we also found moderate fitness costs for 210W
and 181C (-0.85 s.d. and -0.69 s.d. respectively), which were excluded from our analysis
because they lie in HLA epitopes and disrupt binding. The main discrepancy was found
for 215Y, where our methods predicted low fitness costs (- 0.86 s.d.) in contrast to the
SDM data [266]. The fact that reversion rates are high for this mutation indicates that
our estimator has underestimated the real fitness cost of this mutation. This failure may
be also related to the complexity of the mutational pathways at this position, which may
have been oversimplified by our approach (in which we do not distinguish which amino
acid a TDRM reverts to). This deviation is also not surprising since the computational
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predictor underlying our approach is not perfect (42% of deviance in in vitro fitness were
explained in [270]). Overall this comparison thus validates our method but also reveals
that there is potential for improvement and hence our approach should be best viewed
as a proof of principle of using machine-learning approaches in conjunction with in vitro
fitness measurements to assess reversion of TDRM in vivo.
This assessment of the fitness predictor is confirmed by considering the quality of fit of
the different models summarized in Fig 9.2: Starting from an interval-censored survival
model without explanatory variables, adding the information of whether a given TDRM
is present as a mixture reduces the model deviance by 22%. Adding TDRM-fitness as an
explanatory variable reduces the model’s deviance by a further 9%. If we separate fitness
cost into the mean fitness cost of a given mutation type and the corresponding residual
fitness cost (as in Fig 9.2), this 9% results from a 6% of deviance-reduction explained by
the mean fitness cost and 3% by the residual fitness cost. This indicates an important
role of fitness for TDRM reversion; especially given that, firstly, the fitness predictor used
here is not perfect (it explains 42% of deviance of in vitro replicative capacity [270]) and
that, secondly, being a mixture implies that a nucleotide has already started to revert
and hence the corresponding variable represents a very strong determinant of reversion.
Finally, these numbers suggest that the differential fitness-costs of the same mutation in
different genetic backgrounds contribute half as much to the population-level variability
in reversion than different fitness-costs of different mutations. Given the well-described
and strong differences in reversion rates across mutation types this therefore implies an
important role of the genetic background. However, these fractions of deviance explained
by our predicted fitness costs imply that reversion rates also depend on other factors not
captured by in vitro replicative capacity. This includes interactions between host-viral
factors such as HLA escape. Even though we excluded TDRMs known to mediate CTL
escape (see Methods), it is likely that this does not encompass all such escape mutations
or more generally all mutations that affect the interaction of a virus with a given patients
immune system.
Our study had several limitations. One of the limitations of this study was the lack of in-
formation before the first GRT was performed. More specifically, we could not determine
how long a TDRM had already persisted before the first GRT. We studied the reversion
of TDRM from the baseline GRT instead of the infection date of a patient because an
exact infection date was not known for most of the patients and because GRTs at infection
time are typically not available. This approach increased the sample size considerably in
exchange for missing some TDRM that had reverted before the first GRT was performed.
This could explain why K65R or T215F, which are known to revert rapidly, were not
identified in our study. The fast reverting TDRM such as M184V were either missed or
detected right after the infection by GRT, thus the estimated reversion rates were not al-
tered to a large extent and only the sample size may be lower. Another limitation was that
around 40% (67 / 168) of patients carried > 1 TDRM at baseline. Although combinations
of mutations could modulate the fitness costs substantially [178], causing that a given
mutation has varying fitness costs when having different genetic backgrounds, the number
of mutations detected at the first GRT was not found to be associated with the reversion
of TDRM [215]. Additionally we adjusted for different genetic backgrounds including the
residual fitness costs in our model and still found positive associations of reversion rates
with average fitness costs.
In conclusion, our study demonstrated that TDRM showed substantial variation in rever-
sion rates, which were positively associated with the fitness costs these mutations had in
their genetic background.
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9.5 Supplementary
1. S1 Table
S1 Table. Observed frequency at baseline and number of reversion from 
mutations ever observed 
 
Drug Class Mutation Number of reversion / Observed frequency at baseline (percentage) 
NRTI 41L 9 / 45 (20.0) 
 
65R 2 / 3 (66.7) 
 
67G 1 / 5 (20.0) 
 
67N 3 / 14 (21.4) 
 
69D 1 / 1 (100.0) 
 
70E 1 / 1 (100.0) 
 
70R 7 / 11 (63.6) 
 
74I 1 / 1 (100.0) 
 
74V 1 / 3 (33.3) 
 
75A 1 / 1 (100.0) 
 
77L 0 / 1 (0.0) 
 
116Y 1 / 2 (50.0) 
 
151M 0 / 1 (0.0) 
 
184I 1 / 1 (100.0) 
 
184V 5 / 9 (55.6) 
 
210W 4 / 14 (28.6) 
 
215C 6 / 8 (75.0) 
 
215D 4 / 24 (16.7) 
 
215E 1 / 3 (33.3) 
 
215F 1 / 4 (25.0) 
 
215I 2 / 1 (200.0) 
 
215S 8 / 25 (32.0) 
 
215V 0 / 1 (0.0) 
 
215Y 8 / 10 (80.0) 
 
219E 2 / 3 (66.7) 
 
219Q 2 / 15 (13.3) 
 
219R 3 / 4 (75.0) 
 
  
 
 
 
 
Drug Class Mutation Number of reversion / Observed frequency at baseline (percentage) 
PI 23I 1 / 1 (100.0) 
 
24I 0 / 2 (0.0) 
 
30N 1 / 2 (50.0) 
 
46I 5 / 16 (31.2) 
 
46L 5 / 8 (62.5) 
 
47V 3 / 3 (100.0) 
 
48V 0 / 1 (0.0) 
 
50V 1 / 1 (100.0) 
 
53L 0 / 1 (0.0) 
 
54M 0 / 1 (0.0) 
 
54V 1 / 6 (16.7) 
 
73C 1 / 2 (50.0) 
 
73S 2 / 2 (100.0) 
 
76V 1 / 1 (100.0) 
 
82A 2 / 6 (33.3) 
 
82L 0 / 1 (0.0) 
 
82T 1 / 1 (100.0) 
 
83D 0 / 1 (0.0) 
 
84V 1 / 3 (33.3) 
 
85V 1 / 5 (20.0) 
 
88D 1 / 2 (50.0) 
 
90M 2 / 21 (9.5) 
Drug Class Mutation Number of reversion / Observed frequency at baseline (percentage) 
NNRTI 101E 2 / 5 (40.0) 
 
101P 0 / 1 (0.0) 
 
103N 9 / 35 (25.7) 
 
103S 0 / 2 (0.0) 
 
179F 1 / 1 (100.0) 
 
181C 2 / 8 (25.0) 
 
188L 1 / 3 (33.3) 
 
190A 0 / 7 (0.0) 
 
225H 0 / 1 (0.0) 
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Abstract
Background
The most recommended NRTI combinations as first-line antiretroviral treatment for
HIV-1 infection in resource rich settings are tenofovir(TDF)/emtricitabine(FTC), aba-
cavir(ABC)/lamivudine(3TC), TDF/3TC and zidovudine(AZT)/3TC . Different pill num-
bers and dosing frequencies per day among these combinations were rarely considered when
studying their relative efficacy.
Methods
We included patients starting their first-line cART with or switching from the first-line
cART without treatment failure to TDF/FTC, ABC/3TC, TDF/3TC, or AZT/3TC plus
efavirenz or nevirapine. Cox proportional hazard regression was used to investigate the ef-
fect of the different NRTI combinations on two primary outcomes: virological failure (VF)
and emergence of NRTI-resistance. Additionally, we performed a pill burden analysis and
adjusted the model for pill number and dosing frequency.
Results
Compared to TDF/FTC, ABC/3TC had an adjusted hazard ratios (HR) for having VF
of 2.01 (95% CI, 0.86 - 4.55), TDF/3TC 2.89 (1.22 - 6.88), and AZT/3TC 2.28 (1.01 -
5.14), whereas for the emergence of NRTI resistance ABC/3TC had a HR of 1.17 (0.11 -
12.2), TDF/3TC 11.3 (2.34 - 55.3), and AZT/3TC 4.02 (0.78 - 20.7). Differences among
regimens disappeared when models were additionally adjusted for pill burden. However,
non-white population compared to white population and higher pill number per day were
associated with increased risks of VF and emergence of NRTI-resistance: HR of ethnicity
for VF was 2.85 (1.64 - 4.96), for NRTI resistance 3.54 (1.20 - 10.4); HR of pill burden for
VF was 1.41 (1.01 - 1.96), for NRTI resistance 1.72 (0.97 - 3.02).
Conclusions
Pill burden and ethnicity showed a robust association with virological response and emer-
gence of NRTI resistance.
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Background: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in
resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine.
Efficacy studies of these combinations also considering pill numbers, dosing frequencies and ethnicities are rare.
Methods:We included patients starting first-line combination ART (cART) with or switching from first-line cART without
treatment failure to tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine
plus efavirenz or nevirapine. Cox proportional hazards regression was used to investigate the effect of the different
NRTI combinations on two primary outcomes: virological failure (VF) and emergence of NRTI resistance.
Additionally, we performed a pill burden analysis and adjusted the model for pill number and dosing frequency.
Results: Failure events per treated patient for the four NRTI combinations were as follows: 19/1858 (tenofovir/
emtricitabine), 9/387 (abacavir/lamivudine), 11/344 (tenofovir/lamivudine) and 45/1244 (zidovudine/lamivudine).
Compared with tenofovir/emtricitabine, abacavir/lamivudine had an adjusted HR for having VF of 2.01 (95% CI
0.86–4.55), tenofovir/lamivudine 2.89 (1.22–6.88) and zidovudine/lamivudine 2.28 (1.01–5.14), whereas for the
emergence of NRTI resistance abacavir/lamivudine had an HR of 1.17 (0.11–12.2), tenofovir/lamivudine
11.3 (2.34–55.3) and zidovudine/lamivudine 4.02 (0.78–20.7). Differences among regimens disappeared when
models were additionally adjusted for pill burden. However, non-white patients compared with white patients
and higher pill number per day were associated with increased risks of VF and emergence of NRTI resistance: HR
of non-white ethnicity for VF was 2.85 (1.64–4.96) and for NRTI resistance 3.54 (1.20–10.4); HR of pill burden for VF
was 1.41 (1.01–1.96) and for NRTI resistance 1.72 (0.97–3.02).
Conclusions:Although VFand emergence of resistance was very low in the population studied, tenofovir/emtricitabine
appears to be superior to abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. However, it is unclear
whether these differences are due to the substances as such or to an association of tenofovir/emtricitabine regimens
with lower pill burden.
Introduction
More than 25 antiretroviral drugs from 6 different drug classes
against HIV-1 infection are available today. The standard
combination ART (cART) consists of two NRTIs and a potent
third agent, e.g. an NNRTI.1 Recent guidelines recommend tenofo-
vir/emtricitabine or abacavir/lamivudine in combination with
either efavirenz or nevirapine, or rilpivirine for individuals with
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10.1 Introduction
More than 25 antiretroviral drugs from 6 different drug classes against HIV-1 infection are
available today. The standard combination of antiretroviral treatment (cART) consists
of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and a potent third agent,
generally a non-NRTI (NNRTI) or a boosted protease inhibitor (PI/r) or more recently an
integrase inhibitor [53]. For first-line cART including NNRTI, recent treatment guidelines
recommend tenofovir (TDF)/emtricitabine (FTC) or abacavir (ABC)/lamivudine (3TC)
as the preferred NRTI backbone in combination with either efavirenz (EFV) or nevirapine
(NVP), or rilpivirine for individuals with HIV-1-RNA <100000 copies/m` [53, 130]. Alter-
natively, if unavailability or intolerance to other recommended NRTIs exists, TDF/3TC
and zidovudine (AZT)/3TC are recommended [276, 277]. These were widely used in first-
line regimens before the availability of TDF/FTC, ABC/3TC as fixed dose combinations
in resource rich countries and are still widely used in resource limited settings.
Studies directly comparing all these four important NRTI combinations in large popula-
tions are lacking. The relative in vivo efficacy of these recommended NRTI combinations
is unclear. AZT/3TC was shown to have similarly high potency as TDF/FTC containing
EFV in a randomized controlled trial [278] but is rarely the first option nowadays for
treatment in resource rich settings due to toxicity [279], intolerability issues and twice
daily dosing [136]. Although ABC/3TC and TDF/FTC were found in a randomized trial
to provide comparable antiretroviral efficacy for first-line treatment [280], in another clin-
ical trial ABC/3TC showed inferior virological responses than TDF/FTC in patients with
baseline HIV-RNA levels > 100000 copies/m` [129, 281]. ABC/3TC was also associated
with more adverse events including lipid abnormalities [281]. Moreover, some random-
ized trials observed better virological responses for regimens containing TDF/FTC than
TDF/3TC [282] whereas other studies [283, 284] observed equal suppression rates between
the two. On the other hand, a recent observational study comparing treatment-na¨ıve pa-
tients initiating TDF/3TC or TDF/FTC plus a NNRTI found that TDF/3TC led to more
virological failures, however this study did not consider adherence, pill counts, or dosing
frequency as potential confounders [285].
Comparing NRTI backbones is a complex undertaking because they are formulated dif-
ferentially: for TDF/FTC, ABC/3TC once-daily and for AZT/3TC twice-daily fixed dose
combinations (FDC) exist. EFV can be given in combination with FDC but mostly is used
as single tablet regimen including EFV/TDF/FTC. In addition, 3TC can be taken once
or twice daily in contrast to FTC, which has exclusively the once-daily option. Thus, the
daily number of total pills and the maximal dosing frequency can vary substantially among
AZT, ABC, FTC, 3TC, and TDF in NNRTI containing regimens. Randomized clinical
trials mostly compare just two, if at all, backbones against each other. In addition, they
do not necessarily reflect a routine clinical setting because often patients are highly se-
lected due to strict enrolment criteria and men are enrolled over proportionally in general.
However, it is of high importance to examine the treatment efficacy of NRTI backbones
with regards to pill burden and dosing frequency, since governments, health insurances
and third-party payers may soon start to put pressure on using also non-coformulated
ART generics in the future due to considerably lower prices.
Therefore, the aim of this study was to compare TDF/FTC, ABC/3TC, TDF/3TC and
AZT/3TC paired with EFV or NVP as first-line cART regarding virological responses and
emergence of drug-resistance in the representative Swiss HIV Cohort study (SHCS) and
to evaluate the impact of pill burden and dosing frequency on treatment efficacy.
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10.2 Methods
Selection of patients
Our analysis was based on ART-experienced patients from the Swiss HIV Cohort Study
starting treatment up to January 8, 2014. The SHCS, continually enrolling patients aged
16 or older since 1988, is a prospective and nationwide cohort study including a biobank.
The SHCS is representative for the HIV epidemic in Switzerland; it includes at least 53%
of all HIV cases ever diagnosed in Switzerland, 72% of all patients receiving ART, and
69% of the nationwide registered AIDS cases [242]. Ethical committees of all participating
institutions have approved the SHCS, and written informed consent was obtained from all
patients [10, 242].
Resistance data are generated from routine-clinical testing performed by four laboratories,
which were authorized by the Swiss Federal Office of Public Health. All laboratories se-
quenced the protease and the reverse transcriptase gene using population-based sequencing
with commercial assays (Viroseq Vs.1 PE Biosystems; Viroseq Vs. 2, Abbott AG; Vir-
coTYPE HIV-1 Assay, Virco Lab) or in-house methods [286]. They all participate in the
annual quality control evaluation by the Agence Nationale de la Recherche sur le SIDA et
les hpatites virales (ANRS) since 2002. All sequences are entered into the SHCS drug re-
sistance database using SmartGene’s Integrated Dababase Network System (SmartGene,
Zug, Switzerland, IDNS version 3.6.3) [244]. Additionally, we systematically selected and
retrospectively sequenced plasma samples from drug na¨ıve and for treatment failing pa-
tients stored in our biobank, especially for samples obtained before the routine genotyping
was introduced.
To compare the efficacy of the different NRTI backbones (TDF/FTC, ABC/FTC,
ABC/3TC and AZT/3TC) either combined with EFV or with NVP, we identified HIV-
1 infected patients from the SHCS who have initiated their first cART with one of the
regimens mentioned above or switched from their first cART to one of these regimens
for reasons other than treatment failure. Patients were excluded from the analysis if
baseline resistance was identified according to the Stanford database algorithm (mutation
penalty score ≥ 15, Stanford genotypic resistance interpretation algorithm version 7.0:
http://sierra2.stanford.edu/sierra/servlet/JSierra). Patients without complete
documentation of the prescribed tablets (e.g., whether TDF/FTC were given separately
or combined) were further excluded from the sub-analysis in which we tested the effect of
the pill burden on the treatment success.
Study outcomes
Two primary outcomes were analyzed: virological failure (VF) and emergence of NRTI
drug resistance. The latter was defined as the first detection of any major IAS-USA drug
resistance mutation [287] to NRTI following VF. VF was defined as HIV-1 plasma RNA
level ≥ 400 copies/m` after 180 days of continuous treatment. If the subsequent HIV-RNA
was < 400 copies/m`, it was considered as viral blip. Not all patients experiencing VF had
a genotypic resistance test (GRT) performed following VF. Including the subjects in the
resistance analysis, for whom we could not determine whether resistance emerged or not,
would be potentially incorrect because they would be included as if they did not have any
resistance. Thus, we first compared the characteristics of those with and without GRT
following VF within the same regimen group by Wilcoxon rank-sum test. Variables tested
were treatment length, time from treatment initiation to VF, viral load at VF, and the
consecutive viral load at VF. If there was no evidence for a difference we excluded those
with VF but without GRT from the resistance analysis in order to avoid selection bias.
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Statistical methods
We analyzed data with univariable and multivariable Cox proportional hazard models to
estimate Hazard ratios (HRs) with 95% confidence intervals (CIs) and used robust stan-
dard errors to account for possible intra-patient correlations because a patient could be
included twice: 1) first-line cART and 2) switched to cART regimens while suppressed.
Exposure time started at treatment initiation for every treatment episode. Patients were
censored at the time of death, the last visit date, or the end of the treatment, whichever
came first. Regimens were included categorically in the model.
Adjustment comprised all variables with univariable significance, which included age (con-
tinuous), ethnicity (white and non-white, categorical), and treatment starting year (con-
tinuous), and variables decided a priori including baseline HIV-RNA (log10 transformed,
continuous) and baseline CD4 counts (square-root transformed, continuous). Baseline CD4
and HIV-RNA data at the initiation of the first cART were retrieved. Missing baseline
CD4 counts (5%) and HIV-RNA (7%) were imputed using multivariable normal regression
(an iterative Markov chain Monte Carlo method) and estimated by age, sex, ethnicity, in-
clusion center, transmission route, and treatment starting year. In the pill burden analysis
models were adjusted for two more co-variables: pill burden (i.e. the total pill number per
day, continuous), and the maximal dosing frequency per day (once or twice-daily); both
were time-updated variables. Since CD4 counts or pill burden entered categorically did
not improve the model fit, we chose them to be continuous. Collinearity was tested with
variance inflation factors and correlation matrices and none was found.
To test the robustness of our results we performed two sensitivity analyses in which we
either restricted NNRTI drugs to EFV or restricted our study population to patients on
first-line cART. The analyses were performed using Stata 13.0 SE (StataCorp, Texas,
USA).
10.3 Results
Study population
9755 patients have been ART-experienced since 1996 in the SHCS. Among these individ-
uals, 2678 had initiated treatment containing one of the regimens of interest and 1338
had switched from any regimen to one of the regimens of interest. Ninety-nine (7%) pa-
tients from the switching group were excluded due to VF or drug resistance identified at
the time of switching. This resulted in 3917 treatment episodes from 3398 individuals.
Baseline GRT was available for 2477/3398 (73%) patients. 77/3398 (2%) patients had
low-level resistance to the prescribed regimen and therefore were excluded. In total, our
study comprised of 3833 treatment episodes represented by 3321 individuals (Figure 10.1).
Baseline characteristics were summarized in Table 10.1. Overall, statistically significant
differences between groups were observed in all characteristics except for ethnicity.
Virological failures
The following crude numbers of virological failures were observed for the different NRTI
backbones studied (Figure 10.2 A): TDF/FTC, 1858 treatment episodes with 19 failures
(1.0%); ABC/3TC, 387 treatment episodes with 9 failures (2.3%); TDF/3TC, 344 treat-
ment episodes with 11 failures (3.2%); AZT/3TC, 1244 treatment episodes with 45 failures
(3.6%).
In the univariable model the lowest failure rate was observed for TDF/FTC (as reference),
followed by ABC/3TC (HR, 2.38 [95%CI,1.07 - 5.26], p = 0.033), TDF/3TC (HR, 4.04
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9755 ART-experienced patients enrolled in the SHCS 
before Jan.8, 2013
2678 initiated treatment containing one of the 
regimens of interest
1338 switched to one of the regimens of 
interest
99 excluded due to identified VF 
or drug resistance at switching
3917 treatment episodes from 3398 individuals
77 excluded due to resistance to the 
prescribed regimen
3833 treatment episodes from 3321 individuals
Figure 10.1: Patient selection profile
92 CHAPTER 10. RESEARCH PROJECT 3
Treatment groupa TDF/FTC ABC/3TC TDF/3TC AZT/3TC 
 N, (%) N, (%) N, (%) N, (%) 
Total number of patients (n=3321) 1577 (47.5) 274 (8.3) 268 (8.1) 1202 (36.2) 
Median age at baseline (IQRb) 40 (32, 46) 40 (33, 48) 39 (32, 45) 37 (31, 44) 
Ethnicity     
  White 1171 (74.2) 190 (69.3) 204 (76.1) 862 (71.7) 
  Non-white 406 (25.8) 84 (30.7) 64 (23.9) 340 (28.3) 
Gender & Transmission route     
  Homosexual Men (MSM) 873 (55.4) 114 (41.6) 94 (35.1) 387 (32.2) 
  Heterosexual Men (HSXM) 314 (19.9) 67 (24.5) 63 (23.5) 285 (23.7) 
  Heterosexual Women (HSXF) 252 (16.0) 60 (21.9) 73 (27.2) 310 (25.8) 
  Intravenous drug users (IDU) 69 (4.4) 18 (6.6) 29 (10.8) 157 (13.1) 
  Unknown 69 (4.4) 15 (5.5) 9 (3.4) 63 (5.2) 
Median CD4 count at baseline 
(cells/mm3) (IQR) 282 (190, 383) 250 (173, 343) 200 (104, 287) 208 (122, 313) 
Median viral load at baseline 
(log10 copies/ml) (IQR) 
4.5 (3.5, 5.0) 4.2 (2.6, 4.9) 4.7 (3.6, 5.3) 4.7 (3.9, 5.3) 
     
Total number of treatment 
episodes (n=3833) 1858 (48.5) 387 (10.1) 344 (9.0) 1244 (32.5) 
Median treatment initiation year 
(IQR) 
2009 (2008, 
2011) 
2008 (2007, 
2010) 
2005 (2004, 
2006) 
2002 (2000, 
2004) 
First-line treatmentc 1292 (69.5) 198 (51.3) 211 (61.3) 912 (73.4) 
 
 
a. TDF: tenofovir, FTC: emtricitabine, ABC: abacavir, 3TC: lamivudine, 
AZT: zidovudine  
b. IQR: interquartile range 
c. percentage in the bracket indicated the ratio to the total number of 
that specific regimen 
 
Table 10.1: Basic characteristics of study population
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 Virological Failure Virological Failure in pill burden analysis 
 Univariable Multivariable Univariable Multivariable 
 HR 95% CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P 
Regimena             
  TDF/FTC 1   1    1  1   
  ABC/3TC 2.38 1.07-5.26 0.033 2.01 0.89-4.55 0.095 2.15 0.94-4.91 0.069 1.79 0.76-4.23 0.18 
  TDF/3TC 4.04 1.92-8.48 <0.001 2.89 1.21-6.88 0.016 4.29 2.04-9.05 <0.001 2.64 0.94-7.44 0.066 
  AZT/3TC 3.89 2.26-6.69 <0.001 2.28 1.01-5.14 0.046 2.89 1.48-5.63 0.002 3.10 0.51-18.7 0.22 
Age, increase per year 0.97 0.95-0.99 0.005 0.99 0.96-1.01 0.23 0.98 0.96-1.01 0.22 1.00 0.97-1.03 0.95 
Ethnicity             
  White 1   1   1   1   
  Non-white 2.94 1.91-4.53 <0.001 2.67 1.69-4.23 <0.001 2.90 1.70-4.97 <0.001 2.85 1.64-4.96 <0.001 
Gender & Transmission routeb             
  MSM 1   -   1   -   
  HSXM 2.23 1.28-3.88 0.005 -   2.21 1.16-4.19 0.015 -   
  HSXF 1.84 1.00-3.38 0.051 -   1.61 0.76-3.40 0.22 -   
  IDU 2.24 1.04-4.83 0.040 -   1.24 0.37-4.21 0.73 -   
  Unknown 2.72 1.11-6.68 0.029 -   2.06 0.61-7.02 0.25 -   
Square-root of CD4 count 0.95 0.91-0.99 0.023 0.97 0.92-1.02 0.30 0.95 0.90-0.99 0.03 0.97 0.92-1.03 0.35 
Log10 viral load 1.14 0.95-1.36 0.17 1.07 0.88-1.30 0.50 1.18 0.95-1.46 0.13 1.13 0.89-1.44 0.31 
Treatment starting year, increase per year 0.87 0.82-0.92 <0.001 0.94 0.85-1.04 0.22 0.90 0.83-0.97 0.005 1.05 0.93-1.19 0.40 
Pill number per day -   -   1.69 1.31-2.19 <0.001 1.41 1.01-1.96 0.043 
Dosing frequency per day -   -   1.81 1.02-3.19 0.041 0.64 0.12-3.30 0.59 
 
a. TDF: tenofovir, FTC: emtricitabine, ABC: abacavir, 3TC: lamivudine, AZT: zidovudine  
b. MSM: men having sex with men, HSXM: heterosexual men, HSXF: heterosexual women, IDU: intravenous drug users 
Table 10.2: Uni- and multivariable cox proportional hazard analysis for virological failure
The multivariable models were adjusted for all variables indicated, i.e., showing HR
[1.92 - 8.48], p < 0.001) and AZT/3TC (HR, 3.89 [2.26 - 6.69], p < 0.001; Table 10.2, left
part). After adjustment for baseline CD4 count, baseline HIV-1 RNA and all significantly
associated co-variables including age, ethnicity, and year of treatment start, HRs among
regimens decreased in magnitude (ABC/3TC: 2.01 [0.89 - 4.55], p = 0.095; TDF/3TC:
2.89 [1.22 - 6.88], p = 0.016; AZT/3TC: 2.28 [1.01 - 5.14], p = 0.046). Ethnicity was
strongly associated with treatment outcome: the non-white patients were 2.67 times more
likely to experience VF than the white population (95% CI, 1.69 - 4.23, p < 0.001).
Emergence of NRTI resistance
Next we analyzed the relative efficacy of the four NRTI combinations regarding time to
the emergence of any NRTI resistance mutation following VF. However, 9 out of 19 (47%)
failing regimens with TDF/FTC were not genotyped, and the numbers of non-genotyped
treatments from failing treatments containing ABC/3TC, TDF/3TC, and AZT/3TC, re-
spectively were 4 from 9 (44%), 1 from 11 (9%), and 16 from 45 (36%). Wilcoxon rank-sum
test did not find an indication for a difference between patients with and without GRT
following VF. Because we had no alternative means to determine whether drug resistance
had developed in a non-genotyped failure episode, we excluded those without GRT from
this analysis. After exclusion, we detected NRTI resistance in 3 of 1849 (0.2%) TDF/FTC,
1 of 383 (0.3%) ABC/3TC, 9 of 343 (2.6%) TDF/3TC, and 17 of 1228 (1.4%) AZT/3TC
containing regimens that failed (Figure 10.2 B).
In the univariable model the HR of ABC/3TC showed no evidence for an effect on the
emergence of resistance when compared to TDF/FTC (1.72 [0.18 - 16.5], p = 0.64), but
more emergence of NRTI resistance was associated with TDF/3TC (20.4 [5.49 - 75.6],
p < 0.001) and AZT/3TC (9.8 [2.88 - 33.3], p < 0.001; Table 10.3, left part). The
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Figure 10.2: Kaplan-Meier curves for time to (A) VF and (B) emergence of NRTI resistance
in the different treatment groups
TDF indicates tenofovir; FTC, emtricitabine; ABC abacavir; 3TC, lamivudine; AZT, Zidovudine. The
numbers of failure events are shown in parentheses.
10.3. RESULTS 95
 NRTI Resistance NRTI Resistance in pill burden analysis 
 Univariable Multivariable Univariable Multivariable 
 HR 95% CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P 
Regimena             
TDF/FTC 1   1   1   1   
ABC/3TC 1.72 0.18-16.5 0.64 1.17 0.11-12.2 0.90 1.74 0.18-16.7 0.63 1.16 0.10-12.9 0.91 
TDF/3TC 20.4 5.49-75.6 <0.001 11.3 2.34-55.3 0.003 21.0 5.63-78.0 <0.001 5.60 0.71-44.0 0.10 
AZT/3TC 9.80 2.88-33.3 <0.001 4.02 0.78-20.7 0.096 5.84 1.42-24.1 0.015 1.62 0.19-14.1 0.66 
Age, increase per year 0.94 0.91-0.98 0.002 0.97 0.94-1.01 0.21 0.96 0.92-1.00 0.058 0.98 0.94-1.03 0.45 
Ethnicity             
  White 1   1   1   1   
  Non-white 5.41 2.55-11.5 <0.001 4.43 1.85-10.6 0.001 3.84 1.51-9.78 0.005 3.54 1.20-10.4 0.022 
Gender & Transmission routeb             
  MSM 1   -   1   1   
  HSXM 2.85 1.15-7.10 0.024 -   2.98 0.95-9.36 0.061 -   
  HSXF 2.48 0.93-6.58 0.068 -   2.64 0.76-9.11 0.13 -   
  IDU 0.76 0.09-6.11 0.80 -   - - - -   
  Unknown 2.76 0.58-13.0 0.20 -   2.43 0.28-21.0 0.42 -   
Square-root of CD4 count  0.88 0.83-0.94 <0.001 0.88 0.81-0.96 0.002 0.88 0.81-0.94 <0.001 0.89 0.80-1.00 0.042 
Log10 viral load  1.03 0.73-1.45 0.86 0.87 0.67-1.15 0.33 1.30 0.78-2.19 0.32 1.05 0.60-1.83 0.86 
Treatment starting year, increase per year 0.81 0.75-0.87 <0.001 0.91 0.78-1.06 0.23 0.79 0.73-0.86 <0.001 0.98 0.78-1.24 0.90 
Pill number per day -   -   2.83 1.95-4.10 <0.001 1.72 0.97-3.02 0.062 
Dosing frequency per day -   -   2.33 0.91-5.99 0.078 1.19 0.24-5.82 0.83 
 
a. TDF: tenofovir, FTC: emtricitabine, ABC: abacavir, 3TC: lamivudine, AZT: zidovudine  
b. MSM: men having sex with men, HSXM: heterosexual men, HSXF: heterosexual women, IDU: intravenous drug users 
Table 10.3: Uni- and multivariable cox proportional hazard analysis for emergence of NRTI
resistance
The multivariable models were adjusted for all variables indicated, i.e., showing HR
adjusted HR on emergence of NRTI resistance for patients on TDF/3TC compared to
TDF/FTC was 11.3 (2.34 - 55.3, p = 0.003), but HR was not significantly different for
ABC/3TC (1.17 [0.11 - 12.2], p = 0.90) or AZT/3TC (4.02 [0.78 - 20.7], p = 0.096). How-
ever, ethnicity was strongly associated with the emergence of NRTI resistance (non-white
versus white: HR, 4.43 [1.85 -10.6], p = 0.001) in the adjusted model.
Study population in the pill burden analysis
Since pill number and dosing frequency were essential for the pill burden analysis, patients
without full documentation of tablet usage were excluded from this analysis, resulting
in 3088 treatment episodes from 2684 individuals. Given that pill burden and dosing
frequency are time-updated variables, we had 4263 observations in total. Median, minimal
and maximal numbers of total pills were 2, 1 and 6. For the TDF/FTC, ABC/3TC,
TDF/3TC, and AZT/3TC regimen groups the median (IQR) number of total pills was 2
(1,2), 2 (2,3), 4 (4,4), and 3 (3,3), respectively, and the proportions of once-daily regimens
were 97.2%, 92.5%, 81.0%, and 1.4%.
Virological failures in the pill burden analysis
Similar to the original analysis, the univariable analysis of pill burden resulted in the lowest
chance of having VF from TDF/FTC group when compared to the other three regimens
(ABC/3TC: HR, 2.15 [0.94 - 4.91], p = 0.069; TDF/3TC: 4.29 [2.04 - 9.05], p < 0.001;
AZT/3TC: 2.89 [1.48 - 5.63], p = 0.002; Table 10.2, right part). However, contrary to
the original analysis, in which pill burden and dosing frequency were not adjusted, the
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multivariable model did not show evidence for regimen differences (ABC/3TC: HR, 1.79
[0.76 - 4.23], p = 0.18; TDF/3TC: 2.64 [0.93 - 7.44], p = 0.066; AZT/3TC: 3.10 [0.51 -
18.7], p = 0.22). Pill burden was associated with VF both in the univariable (HR,1.69
[1.31 - 2.19], p < 0.001; Figure 10.3 A) and the multivariable models (HR,1.41 [1.01 -
1.96], p = 0.043). In addition, ethnicity (HR,2.85 [1.64 - 4.96], p < 0.001) remained a
strong predictor for having VF after adjustment. In contrast to pill burden, we did not
find association of dosing frequency with VF after adjustment (HR, 0.64 [0.12 - 3.30],
p = 0.59).
Emergence of NRTI resistance in the pill burden analysis
Results followed the same pattern as for results on VF in the pill burden analysis. Evidence
for effects of TDF/3TC and AZT/3TC in the univariable model (ABC/3TC: HR, 1.74 [0.18
- 16.7], p = 0.63; TDF/3TC: 21.0 [5.63 - 78.0], p < 0.001; AZT/3TC: 5.84 [1.42 - 24.1],
p = 0.015; Table 10.3, right part) was not found after adjustment (ABC/3TC: HR, 1.16
[0.10 - 12.9], p = 0.91; TDF/3TC: 5.60 [0.71 - 44.0], p = 0.10; AZT/3TC: 1.62 [0.19 - 14.1],
p = 0.66), but ethnicity remained a strong risk factor (HR,3.54 [1.20 - 10.4], p = 0.022).
At the same time, we observed a significant effect of pill burden in the univariable model
(HR, 2.83 [1.95 - 4.10], p < 0.001; Figure 10.3 B) and a trend in the multivariable model
(HR, 1.72 [0.97 - 3.02], p = 0.062) to be associated with the emergence of NRTI resistance.
Dosing frequency, however, again showed no effect on the emergence of NRTI resistance
(HR, 1.19 [0.24 - 5.82], p = 0.83).
Sensitivity analyses
Sensitivity analyses, in which we restricted NNRTI to EFV or our study population to
patients on first-line treatment only, robustly showed qualitatively similar results. When
adjusted additionally for pill burden and dosing frequency, evidence for effects of regi-
mens both on VF and on the emergence of NRTI resistance was not detected. However,
one distinct exception was observed: the ABC/3TC treatment group became a stronger
predictor for VF in the model restricting to the first-line patients (HR, 2.93 [1.06 - 8.13],
p = 0.039; pill burden analysis: HR, 3.13 [1.10 - 8.87], p = 0.032). Pill burden was con-
stantly observed to have an impact (restricting to first-line on VF: HR, 1.46 [1.01 - 2.13],
p = 0.046; on resistance: HR, 2.25 [1.21 - 4.18], p = 0.011; restricting to EFV on VF: HR,
1.66 [1.17 - 2.37], p = 0.005; on resistance: HR, 2.14 [1.04 - 4.41], p = 0.038) and ethnicity
remained strongly predictive of experiencing VF and emergence of NRTI resistance when
restricting to first-line (on VF: HR, 2.66 [1.56 - 4.51], p < 0.001; on resistance: HR, 3.32
[1.36 - 8.15], p = 0.009; in pill burden analysis on VF: HR, 2.71 [1.41 - 5.21], p = 0.003; on
resistance: HR, 2.50 [0.76 - 8.28], p = 0.13) and restricting to EFV (on VF: HR, 2.74 [1.67
- 4.47], p < 0.001; on resistance: HR, 5.52 [2.01 - 15.2], p = 0.001; in pill burden analysis
on VF: HR, 3.17 [1.72 - 5.85], p < 0.001; on resistance: HR, 4.89 [1.25 - 19.2], p = 0.023).
10.4 Discussion
In this large study, representative of the treatment history of a whole country, we compared
virological failure rates and emergence of NRTI resistance of four major NRTI combina-
tions TDF/FTC, ABC/3TC, TDF/3TC, and AZT/3TC combined with either EFV or
NVP in a real-world clinical setting. Treatment failure rates and frequency of resistance
emergence was remarkably low in our setting. Failure frequencies ranged from 1.0% for the
TDF/FTC to 3.6% for the AZT/3TC treatment group, and the rate of NRTI resistance
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Figure 10.3: Kaplan-Meier curves for time to (A) VF and (B) emergence of NRTI resistance
in the different treatment groups
TDF indicates Tenofovir; FTC, Emtricitabine; ABC Abacavir; 3TC, Lamivudine; AZT, Zidovudine. The
numbers of failure events are shown in parentheses.
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was even lower ranging from 0.2% for TDF/FTC to 2.6% for TDF/3TC. In univariable
and multivariable analyses we found that ABC/3TC, TDF/3TC and AZT/3TC containing
regimens had a more than two folds higher risk leading to VF than TDF/FTC contain-
ing regimens. TDF/3TC was more often associated with emergence of NRTI-resistance
than TDF/FTC. Among regimens other than TDF/FTC, no clear superiority was found.
When adjusting for pill burden and dosing frequency, we found that higher number of pills
but not dosing frequency was associated with VF and emergence of NRTI drug resistance.
Additionally, a very strong predictor of VF and resistance emergence across all analyses
was ethnicity. Specifically, treatment responses in white patients compared to non-white
patients were better.
Our findings are of high relevance in the light of the upcoming availability of generic drugs.
It can be envisioned that health care systems and health insurance companies may build
up considerable pressure on health care providers to use cheap drugs independent of pill
numbers, tolerability or toxicity. Here, we showed that this strategy most likely would
result in higher rates of treatment failures and more frequent emergence of resistance.
Thus, even when generics are available, the aim to minimize the pill burden should be
maintained, however, dosing frequency is less important in this regard.
The strength of this study was the representativeness. On the other hand, limitations of
our study were that the sample size was not large enough to differentiate more between
NRTI backbones and that events of VF or NRTI resistance were few. However even in
the pill burden analysis in which we did not find evidence for an effect between regimens,
HR of ABC/3TC, TDF/3TC, and AZT/3TC comparing to TDF/FTC for having VF and
emergence of NRTI resistance were indeed all above one but had very wide CI. To this
point it was difficult to determine whether power issues have limited our ability to docu-
ment evidence. Studies with more individuals are needed to evaluate the relative efficacy
of the regimens and to disentangle the effects of pill burden and the type of regimen.
However, even with our sample size we could observe effects of pill burden and ethnicity.
Hence, our data suggested that both ethnicity and pill burden was at least equally impor-
tant as treatment itself in affecting treatment efficacy and had decisive impact on VF and
the emergence of NRTI resistance.
The effect on viral responses of pill burden but not dosing frequency found in our anal-
ysis was consistent with results from a recent meta-analysis [151]. A large and long-term
randomized trial also found that twice-daily regimens containing Raltegravir performed at
least as well as once-daily regimens [288]. Additionally, in a previous study, sub-Saharan
African patients in Switzerland showed a higher risk of virological failure on cART [289].
Their inferior self-reported adherence [289] [148] could possibly explain the strong and
robust effect of ethnicity found in our analyses.
Our study included not only treatment-na¨ıve patients initiating their first cART but also
patients switching from the first cART if they did not have VF or resistance detected at
or before switching. Several potential problems should be noted in this respect: First,
second-line patients started treatment with fully suppressed HIV-1-RNA. As a result, the
risk of developing drug resistance could be smaller than for first-line patients because fail-
ure during the time to achieve viral suppression was not possible by definition. However,
this was the case for all four regimens, thus no bias could exist. Second, for patients
whose NRTI backbone was identical in the first and the second cART (i.e., only the third
agent was changed), it was possible that drug resistance had developed as minor variants
during the first cART but was not detected. As a result, second-line treatment might
have failed sooner than first-line treatment. However, sensitivity analyses including only
first-line patients confirmed that our results were robust, apart from the higher HR of
ABC/3TC containing regimens on VF. The difference of ABC/3TC suggested again that
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studies with a larger sample size are needed in determining the relative efficacy of these
NRTI combinations.
In conclusion, pill burden and ethnicity showed robust associations with virological re-
sponses and emergence of NRTI resistance. Studies with more individuals and failure
events are needed to disentangle the effects of pill burden and the drug regimens.
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Discussion
Drug resistance is one of the major concerns jeopardizing treatment success for bacterial,
mycobacterial, parasitic, and viral infections. It is almost inevitable that, whenever
antimicrobial treatments become available, drug resistance to those treatments emerges
over time. This also holds true for HIV-1. Despite the great success of antiretroviral
treatment, drug resistance remains an obstacle to control HIV-1 replication at both the
individual and population levels. Although there are more than 25 antiretroviral drugs
available today and new drugs are continuously developed, treatment options are still
limited for some HIV-1 infected individuals mostly due to drug resistance acquired from
suboptimal therapies (e.g., mono- or dual-therapy), with which they were treated in the
early days. Fortunately, since very early on, the newest technologies and high quality
surveillance methods have been applied to the HIV pandemic. Longitudinal observational
cohorts enabled the study of the emergence and mechanisms of resistance from the very
beginning in a systematic way for this disease.
For every observational epidemiological study, a representative database is essential
for achieving high quality. The SHCS and the SHCS drug resistance databases are
characterized by a high quality and a high density of data. They provide a highly valuable
resource for many epidemiologists to study the many facets of HIV-1 including drug
resistance at the population level.
Acquired HIV-1 drug resistance represents the initial source of circulating resistance
mutations. In most resource-rich countries, a decreasing prevalence of acquired drug
resistance mutations has been documented over the years; however, the prevalence of
transmitted drug resistance mutations has not decreased in these countries. I studied this
apparent paradox in my Research Project 1. The aim of this project was to understand
the dynamics between acquired and transmitted drug resistance at a population level.
This project shows that transmission of HIV-1 drug resistance mutations was under a
transient control when a new drug class was introduced, but increased in the years when
no new drug was introduced. It also shows that treatment-na¨ıve individuals formed an
important source for transmitted drug resistance mutations, especially mutations with
lower fitness cost.
It is generally believed that differential persistence of transmitted drug resistance
mutations is caused, at least partially, by variations in fitness costs of the mutations. In
my Research Project 2 I used in vivo data to study this topic, and found that transmitted
drug resistance mutations persist longer in the absence of drug pressure when these
mutations have a lower fitness cost, which is both true for fitness cost among different
mutations and among different genetic backgrounds of the same mutation. As a result,
higher fitness mutations, either by nature or by regained fitness through compensatory
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mutations, persist longer in a treatment-na¨ıve population, and have a greater chance to
be transmitted and to survive the transmission bottleneck.
These results raise a warning: Switzerland has optimized clinical and public health
circumstances with universal access to antiretroviral treatment and extensive use of drug
resistance and viral load testing. Therefore, even in an optimal setting, it appears infeasi-
ble to reduce the transmission of drug resistance mutations. Consequently, containing the
HIV-1 epidemic and transmission of HIV-1 drug resistance in resource-limited countries
will be more challenging. Limitation of drug options in these countries could lead to
increasing prevalence of transmitted drug resistance mutations over time. Moreover,
especially mutations in genetic backgrounds that cause lower fitness costs would have
a higher chance to spread. In resource-limited settings where surveillance of the HIV-1
infection and drug resistance is usually poor, and availability of different drug classes is
limited for large populations, specific mutations may dominate in the infected populations
in the long run. Improving surveillance of the HIV-1 infection, enhancing availability of
all drug classes universally, and treating infected patients early on play an important role
in containing transmission of drug resistance and transmission of HIV in general.
In addition to containing the spread of transmitted drug resistance, another key factor to
successfully reduce the number of HIV-1 infection is the availability of potent treatment.
Newer drugs have been found to be less toxic and more potent. The issue of reducing
pill burden has also gained increasing attention. In Research Project 3, I took into
account the possible influence of pill burden and dosing frequency on treatment efficacy,
and compared the relative potency of the four mostly used NRTI combinations over
time: TDF/FTC, ABC/3TC, TDF/3TC, and AZT/3TC. These four combinations range
from more historical NRTI drugs, which have more tolerability issues, higher dosing
frequency, and higher pill burden, to the latest NRTI drugs, which have the option
of the once-daily one-pill formula. Results showed that, in addition to the effect of
regimens themselves, higher pill burden and non-white patients are more associated with
experiencing virological failures and the emergence of NRTI resistance. Therefore, pill
burden and ethnicity might play an important role in influencing treatment efficacy.
Drug resistance is a complex and dynamic topic. These three research projects contributed
to a better understanding of the interaction of acquired and transmitted drug resistance
at a population level. We believe that containing drug resistance is certainly one of the
key factors in controlling the HIV-1 infection. It is therefore important to continuously
monitor transmission and emergence of drug resistance, and to start treatment early.
Continuously developing new drugs and making all drugs universally available are also
of high importance. For this purpose, maintaining longitudinal observational databases
of high quality in different parts of the world are essential efforts to control the HIV-1
epidemic, in particular, because eradication or a vaccine are not yet within reach.
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